清眩颗粒对伴及不伴OSA的高血压患者血管内皮功能的影响
|
摘要
1目的
1.1系统评价分析西药钙离子通道阻滞剂治疗伴睡眠呼吸暂停(obstructive sleep apnea, OSA)高血压患者的疗效,以及中药治疗OSA的疗效,为伴OSA高血压患者选择合理的药物降低血压并改善OSA提供一定的荟萃分析依据。
1.2研究伴及不伴OSA高血压患者的血压变异性、内皮功能和OSA的相关性,以及中药清眩颗粒对血压变异性、内皮功能和OSA的影响,为此类患者的中西医诊治提供一定的临床研究依据。
2方法
2.1系统评价研究方法
本研究有2个系统评价,分别是钙离子通道阻滞剂治疗伴OSA高血压患者降压疗效Meta分析,以及中药治疗OSA疗效的Meta分析。两个Meta分析方法大致相同,具体包括：检索CNKI、CBM、VIP、MEDLINE、Embase、Cochrane图书馆(C1)中Cochrane系统评价资料库(CDSR)及Cochrane对照试验注册资料库(CCTR),检索至2011年1月各资料库所有可得文献。采用Cochrane协作网提供的Revman5 (Review Manager5)软件分别分析钙离子通道阻滞剂治疗伴OSA高血压患者降压疗效以及中医药治疗OSA的疗效,根据Cochrane协作网推荐的GRADE (Grading of Recommendations Assessment, Development and Evaluation)标准用GRADEprofiler软件对RCT的质量进行评价。
2.2临床试验研究方法
本研究采用分层随机双盲安慰剂对照方法。
2.2.1纳入阴虚阳亢型轻中度高血压患者90例,对患者行便携式睡眠仪监测、24小时动态血压(ABPM)监测,观察并分析患者血压的均值、变异性、及昼夜节律和OSA的关系；用肱动脉超声技术评价内皮依赖性血管舒张功能(flow-mediated dilation,FMD),并从内皮相关指标(NO/ET-1、hs-CRP和肾素-血管经张素-醛固酮系统)探讨其作用机理。采用多元逐步回归法分析OSA和血压及内皮功能的关系。
2.2.2根据患者OSA诊断结果,分为伴OSA高血压和不伴OSA高血压两个亚组,每个亚组再随机分为试验组和对照组。在氨氯地平常规治疗的基础上,试验组加予清眩颗粒,对照组加予安慰剂,一共干预2个月。用广义线性模型协方差分析血压、内皮和OSA各相关指标治疗前后的差值,以比较清眩颗粒的疗效,并分析OSA对治疗结果的影响。
3结果
3.1系统评价结果
3.1.1钙离子通道阻滞剂治疗伴OSA高血压患者降压疗效Meta分析
钙离子通道阻滞剂在改善收缩压、舒张压方面与对照组比较有改善的趋势,但是无统计学意义(P>0.05)。在降低心率方面与对照组比较有统计学意义(P<0.05)。在改善睡眠时间、睡眠效率、深睡眠、REM期睡眠方面与对照组比较无统计学意义(P>0.05)。GRADE评分表明研究结果质量均为低或极低质量。
3.1.2中医药治疗OSA的疗效Meta分析
与常规西医治疗相比,加上中药汤剂可改善OSA患者总睡眠时间、低通气指数、低通气总时间、90%以下氧饱和度时间,和对照组比较,差异有统计学意义(P<0.05)。但在改善临床有效率、暂停指数AI、90%以下氧饱和度次数、平均心率方面,则中药组和对照组差异没有统计学意义(P>0.05)。GRADE评分表明研究结果质量均为低或极低质量。
3.2临床试验研究结果
3.2.1伴和不伴OSA的高血压患者血压比较
与不伴OSA的高血压患者相比,伴OSA患者的血压变异性和非杓型血压发生率明显增高,夜间血压下降率明显降低(P<0.05)；其中夜间平均收缩压、24h收缩压SD与睡眠呼吸暂停低通气指数(apnea hypopnea index, AHI)呈正相关,夜间收缩压下降率和AHI呈负相关(P<0.05)；
3.2.2伴和不伴OSA的高血压患者内皮功能比较
和不伴OSA的高血压患者相比,伴OSA患者FMD%、NO、NO/ET明显降低,ET-1、PRA、AngⅡ、ALD明显增高(P<0.05)；其中PRA、AngⅡ和AHI呈正相关,NO/ET与AHI呈负相关(P<0.05)。
3.2.3中药清眩颗粒干预伴和不伴OSA的高血压患者疗效分析
3.2.3.1总体患者试验组和对照组疗效分析
在扣除了是否伴OSA和指标基线水平差异的干扰后,发现总体患者以下指标的下降幅度试验组大于对照组(P(a)<0.05)：24h收缩压SD、日间收缩压SD、夜间收缩压SD、24h舒张压SD、24h舒张压CV、日间舒张压SD、夜间舒张压SD、心率、ET、AngⅡ;总体患者以下指标的升高幅度试验组大于对照组(P(a)<0.05):FMD、NO/ET比值。
3.2.3.2 OSA对疗效影响
在扣除了不同药物和指标基线水平的干扰后,发现OSA可以减少以下指标的下降幅度(P(b)<0.05)从而减弱了药物的疗效：夜间平均收缩压、24h收缩压SD、日间收缩压SD、夜间收缩压SD、24h舒张压SD、24h舒张压CV、日间舒张压SD、夜间舒张压SD、夜间舒张压CV、心率、hs-CRP、PRA、AngⅡ、ALD; OSA可以减少以下指标的升高幅度(P(b)<0.05)夜间收缩压下降率、夜间舒张压下降率、FMD、NO、NO/ET比值。
3.2.3.3亚组内分析：
伴OSA患者：24h收缩压SD、24h舒张压SD、日间收缩压SD、日间舒张压SD、夜间收缩压SD、夜间舒张压SD、AngⅡ下降幅度试验组大于对照组(P<0.05); NO/ET比值升高幅度试验组大于对照组(P<0.05)。
不伴OSA患者：24h收缩压SD、24h舒张压CV、日间收缩压SD、日间舒张压SD、夜间舒张压SD、ET-1、hs-CRP、AngⅡ下降幅度试验组大于对照组(P<0.05); FMD、NO/ET比值升高幅度试验组大于对照组(P<0.05)。
3.2.3.4清眩颗粒对OSA的影响
清眩颗粒没有加重OSA患者的病情(P>0.05),还可以减少HI(P<0.05),改善OSA患者低通气情况。
4结论
4.1系统评价提示钙离子通道阻滞剂对血压水平及OSA的改善没有明显优势,中药可以一定程度改善OSA,但仍需大量高质量研究进一步验证。
4.2伴OSA患者的血压变异性增高,昼夜节律紊乱；内皮舒缩功能、炎症反应和RAAS异常；OSA还可减弱降压药对这些指标的治疗作用。
4.3清眩颗粒可以改善高血压患者的血压变异性,促进内皮功能恢复,平衡内皮舒缩因子比例,抑制AngⅡ的过度升高；同时对OSA的低通气指数还有一定的改善作用,可在临床上进一步研究加以验证。
1 Objectives
1.1 To evaluate the effect of calcium channel blockers on hypertensive patients with obstructive sleep apnea(OSA), and to assess the effect of Chinese medicine on OSA patients, so as to provide evidences for reasonable medicine selection to lower blood pressure and improve OSA for these patients.
1.2 To analyze the correlation among blood pressure variability, endothelial function and obstructive sleep apnea in hypertensive patients with and without OSA, and to observe the effect of Qingxuan granule on these patients, so as to provide clinical basis for the diagnosis and treatment of these patients.
2 Methods
2.1 Methods of systemic review
This study includes two systemic reviews, one is to evaluate the effect of calcium channel blockers on hypertensive patients with obstructive sleep apnea(OSA), and the other is to assess the effect of Chinese medicine on OSA. The two systemic reviews are of the same methods:Databases of CNKI、CBM、VIP、MEDLINE、Embase、CDSR、CCTR were searched for all available data till January 2011. RevMan 5 software was used to conduct meta-analysis. GRADE profiler was used to assess the quality of the included trials.
2.2 Clinical trial of Qingxuan granule
This study is a stratified, randomized, doubled-blind, placebo-controlled clinical trial.
2.2.1 90 mild and moderate hypertensive patients with Yin deficiency and Yang hyperactivity syndrome were enrolled into the study. Each one received portable sleep monitoring,24hour Ambulatory Blood Pressure monitoring(ABPM), and blood pressure mean values, blood pressure variability(BPV), blood pressure circadian rhythm and obstructive sleep apnea(OSA) were collected and their correlation was analyzed:endothelial function was evaluated by flow-mediated dilation (FMD), also nitric oxide/endothelin-1(NO/ET-1)、high-sensitivity C-reactive protein(hs-CRP)、and rein-angiotensin-aldosterone system (RAAS) were tested to explore the functional mechanism. Stepwise regression was used to analyze the correlation of OSA,blood pressure and endothelial function.
2.2.2 According to the OSA diagnosis, the hypertensive patients were assigned into two subgroups, one with OSA, the other without OSA; and in each subgroup, patients were randomized into treatment group and control group. All of the patients were treated by amlodpine, in addition, Qingxuan granule was given to the treatment group, and placebo was given to the control goup, respectively. After 2months treatment, the difference (D-value) of the blood pressure, endothelial and OSA index between pretreatment and post-treatment were analyzed by covariance analysis in generalized linear model, so as to investigate the treatment effects of Qingxuan granule, and the impacts of OS A on the D-value in these patients.
3 Results
3.1 Results of systematic review
3.1.1 The effect of calcium channel blockers on hypertensive patients with obstructive sleep apnea(OSA), a Meta-analysis.
Compared with control group, though not statistically significance, calcium channel blockers shows a tendency to improve systolic pressure(SBP), diastolic pressure(DBP), (P>0.05) Heart rate was significantly lower after the treatment with calcium channel blockers than the control group; and no significant difference was found in total sleep time, sleep efficiency, deep sleep, and REM stage sleep between these two groups (P>0.05). According to GRADE, the quality of all the results was low or very low.
3.1.2 The effect of Chinese medicine on OS A patients, a Meta-analysis. Compared with conventional western treatment, the addition of Chinese medicine could significantly improve the OSA patients'total sleep time, hypopnea index(HI), total hypopnea time, the time of desaturation less than 90% (P<0.05). No significant difference was found in improving clinical efficiency, apnea index(AI), the numbers of times of desaturation less than 90%,mean heart rate (P>0.05). According to GRADE, the quality of all the results was low or very low.
The results of clinical trials
3.2.1 Comparison of blood pressure between hypertensive patients with OSA and without OSA The blood pressure variability and the occurrence of non-dipper hypertension were significantly higher in hypertensive patients with OSA than those without OSA, while night time blood pressure fall rate was significantly lower in patients with OSA than those without OSA. (P<0.05). AHI had positive correlation with night time SBP and 24 hour SBP SD, and negative correlation with night time SBP fall rate (P<0.05)
3.2.2 Comparison of endothelial function between hypertensive patients with OSA and those without OSA
FMD%,NO,NO/ET were significantly lower in hypertensive patients with OSA than those without OSA, while ET-1、PRA、A ngⅡ、ALD were significantly higher in patients with OSA than those without OSA (P<0.05); AHI had positive correlation with PRA and AngⅡ, and negative correlation with NO/ET ratio (P<0.05)
3.2.3 Analysis of Qingxuan granule's curative effect on hypertensive patients with and without OSA
3.2.3.1 Analysis of curative effect on treatment group and control group for all patients
After subtracting the interference from OSA and index'baseline levels, the following indexes' declined more in treatment group than in control group (P(a)<0.05):24hSBP SD、daytime SBP SD、night time SBP SD、24hDBP SD、24hDBP CV、daytime DBP SD、night time DBP SD、heart rate、ET、AngⅡ; and the following indexes increased more in treatment group than control group (P(a)<0.05):FMD and NO/ET ratio. 3.2.3.2 Impacts of OSA on curative effect
After filtering out the interference from different treatments and index'baseline levels, the following indexes declined less in patients with OSA than those without OSA:night time SBP、24hSBP SD、daytimeSBP SD、night timeSBP SD、24hDBP SD、24hDBP CV、daytimeDBP SD、night time DBP SD、night time DBP CV、heart rate、hs-CRP、PRA、AngⅡ、ALD; and the following indexes increased less in patients with OSA than those without OSA:night time SBP fall rate, night time DBP fall rate, FMD,NO,NO/ET ratio.
3.2.3.3 Analysis of subgroup
In hypertensive patients with OSA,the following indexes declined more in treatment group than control group:24hSBP SD、24hDBP SD、daytimeSBP SD、daytimeDBP SD、night timeSBP SD、night time DBP SD、AngⅡ(P<0.05); and the following indexes increased more in treatment group than control group:NO/ET ratio (P<0.05)
In hypertensive patients without OSA, the following indexes declined more in treatment group than control group:24hSBP SD、24hDBP CV、daytimeSBP SD、daytimeDBP SD、night time DBP SD、ET-1、hs-CRP、AngⅡ; and the following indexes increased more in treatment group than control group:FMD、NO/ET ratio (P<0.05)
3.2.3.4 Impact of Qingxuan granule on OSA
No significant difference was found in OSA' index after taking Qingxuan granule (P>0.05), with the exception that HI decreased and hypopnea improved (P<0.05)
4 Conclusions
4.1 The result of systematic review suggest that calcium channel blockers is not superior to control group in improving blood pressure level and OSA (P>0.05), while Chinese medicine could improve OSA to a certain extent (P<0.05); a large number of high quality researches are still needed to prove this result.
4.2 In hypertensive patients with OSA the blood pressure variability increased, circadian rhythm was out of order; the endothelial relaxing and contracting function, inflammatory reaction, and RAAS were not normal; OSA could also weaken the curative effect of hypotensive drugs on these indexes.
4.3 For hypertensive patients, Qingxuan granule could improve the blood pressure variability, promote the recovery of endothelial function, balance the endothelial relaxing and contracting ratio, control the excessive increase of AngⅡ; also Qingxuan granule could help to decrease the hypopnea index in OSA, and further study is needed to verify this result.
1.1系统评价分析西药钙离子通道阻滞剂治疗伴睡眠呼吸暂停(obstructive sleep apnea, OSA)高血压患者的疗效,以及中药治疗OSA的疗效,为伴OSA高血压患者选择合理的药物降低血压并改善OSA提供一定的荟萃分析依据。
1.2研究伴及不伴OSA高血压患者的血压变异性、内皮功能和OSA的相关性,以及中药清眩颗粒对血压变异性、内皮功能和OSA的影响,为此类患者的中西医诊治提供一定的临床研究依据。
2方法
2.1系统评价研究方法
本研究有2个系统评价,分别是钙离子通道阻滞剂治疗伴OSA高血压患者降压疗效Meta分析,以及中药治疗OSA疗效的Meta分析。两个Meta分析方法大致相同,具体包括：检索CNKI、CBM、VIP、MEDLINE、Embase、Cochrane图书馆(C1)中Cochrane系统评价资料库(CDSR)及Cochrane对照试验注册资料库(CCTR),检索至2011年1月各资料库所有可得文献。采用Cochrane协作网提供的Revman5 (Review Manager5)软件分别分析钙离子通道阻滞剂治疗伴OSA高血压患者降压疗效以及中医药治疗OSA的疗效,根据Cochrane协作网推荐的GRADE (Grading of Recommendations Assessment, Development and Evaluation)标准用GRADEprofiler软件对RCT的质量进行评价。
2.2临床试验研究方法
本研究采用分层随机双盲安慰剂对照方法。
2.2.1纳入阴虚阳亢型轻中度高血压患者90例,对患者行便携式睡眠仪监测、24小时动态血压(ABPM)监测,观察并分析患者血压的均值、变异性、及昼夜节律和OSA的关系；用肱动脉超声技术评价内皮依赖性血管舒张功能(flow-mediated dilation,FMD),并从内皮相关指标(NO/ET-1、hs-CRP和肾素-血管经张素-醛固酮系统)探讨其作用机理。采用多元逐步回归法分析OSA和血压及内皮功能的关系。
2.2.2根据患者OSA诊断结果,分为伴OSA高血压和不伴OSA高血压两个亚组,每个亚组再随机分为试验组和对照组。在氨氯地平常规治疗的基础上,试验组加予清眩颗粒,对照组加予安慰剂,一共干预2个月。用广义线性模型协方差分析血压、内皮和OSA各相关指标治疗前后的差值,以比较清眩颗粒的疗效,并分析OSA对治疗结果的影响。
3结果
3.1系统评价结果
3.1.1钙离子通道阻滞剂治疗伴OSA高血压患者降压疗效Meta分析
钙离子通道阻滞剂在改善收缩压、舒张压方面与对照组比较有改善的趋势,但是无统计学意义(P>0.05)。在降低心率方面与对照组比较有统计学意义(P<0.05)。在改善睡眠时间、睡眠效率、深睡眠、REM期睡眠方面与对照组比较无统计学意义(P>0.05)。GRADE评分表明研究结果质量均为低或极低质量。
3.1.2中医药治疗OSA的疗效Meta分析
与常规西医治疗相比,加上中药汤剂可改善OSA患者总睡眠时间、低通气指数、低通气总时间、90%以下氧饱和度时间,和对照组比较,差异有统计学意义(P<0.05)。但在改善临床有效率、暂停指数AI、90%以下氧饱和度次数、平均心率方面,则中药组和对照组差异没有统计学意义(P>0.05)。GRADE评分表明研究结果质量均为低或极低质量。
3.2临床试验研究结果
3.2.1伴和不伴OSA的高血压患者血压比较
与不伴OSA的高血压患者相比,伴OSA患者的血压变异性和非杓型血压发生率明显增高,夜间血压下降率明显降低(P<0.05)；其中夜间平均收缩压、24h收缩压SD与睡眠呼吸暂停低通气指数(apnea hypopnea index, AHI)呈正相关,夜间收缩压下降率和AHI呈负相关(P<0.05)；
3.2.2伴和不伴OSA的高血压患者内皮功能比较
和不伴OSA的高血压患者相比,伴OSA患者FMD%、NO、NO/ET明显降低,ET-1、PRA、AngⅡ、ALD明显增高(P<0.05)；其中PRA、AngⅡ和AHI呈正相关,NO/ET与AHI呈负相关(P<0.05)。
3.2.3中药清眩颗粒干预伴和不伴OSA的高血压患者疗效分析
3.2.3.1总体患者试验组和对照组疗效分析
在扣除了是否伴OSA和指标基线水平差异的干扰后,发现总体患者以下指标的下降幅度试验组大于对照组(P(a)<0.05)：24h收缩压SD、日间收缩压SD、夜间收缩压SD、24h舒张压SD、24h舒张压CV、日间舒张压SD、夜间舒张压SD、心率、ET、AngⅡ;总体患者以下指标的升高幅度试验组大于对照组(P(a)<0.05):FMD、NO/ET比值。
3.2.3.2 OSA对疗效影响
在扣除了不同药物和指标基线水平的干扰后,发现OSA可以减少以下指标的下降幅度(P(b)<0.05)从而减弱了药物的疗效：夜间平均收缩压、24h收缩压SD、日间收缩压SD、夜间收缩压SD、24h舒张压SD、24h舒张压CV、日间舒张压SD、夜间舒张压SD、夜间舒张压CV、心率、hs-CRP、PRA、AngⅡ、ALD; OSA可以减少以下指标的升高幅度(P(b)<0.05)夜间收缩压下降率、夜间舒张压下降率、FMD、NO、NO/ET比值。
3.2.3.3亚组内分析：
伴OSA患者：24h收缩压SD、24h舒张压SD、日间收缩压SD、日间舒张压SD、夜间收缩压SD、夜间舒张压SD、AngⅡ下降幅度试验组大于对照组(P<0.05); NO/ET比值升高幅度试验组大于对照组(P<0.05)。
不伴OSA患者：24h收缩压SD、24h舒张压CV、日间收缩压SD、日间舒张压SD、夜间舒张压SD、ET-1、hs-CRP、AngⅡ下降幅度试验组大于对照组(P<0.05); FMD、NO/ET比值升高幅度试验组大于对照组(P<0.05)。
3.2.3.4清眩颗粒对OSA的影响
清眩颗粒没有加重OSA患者的病情(P>0.05),还可以减少HI(P<0.05),改善OSA患者低通气情况。
4结论
4.1系统评价提示钙离子通道阻滞剂对血压水平及OSA的改善没有明显优势,中药可以一定程度改善OSA,但仍需大量高质量研究进一步验证。
4.2伴OSA患者的血压变异性增高,昼夜节律紊乱；内皮舒缩功能、炎症反应和RAAS异常；OSA还可减弱降压药对这些指标的治疗作用。
4.3清眩颗粒可以改善高血压患者的血压变异性,促进内皮功能恢复,平衡内皮舒缩因子比例,抑制AngⅡ的过度升高；同时对OSA的低通气指数还有一定的改善作用,可在临床上进一步研究加以验证。
1 Objectives
1.1 To evaluate the effect of calcium channel blockers on hypertensive patients with obstructive sleep apnea(OSA), and to assess the effect of Chinese medicine on OSA patients, so as to provide evidences for reasonable medicine selection to lower blood pressure and improve OSA for these patients.
1.2 To analyze the correlation among blood pressure variability, endothelial function and obstructive sleep apnea in hypertensive patients with and without OSA, and to observe the effect of Qingxuan granule on these patients, so as to provide clinical basis for the diagnosis and treatment of these patients.
2 Methods
2.1 Methods of systemic review
This study includes two systemic reviews, one is to evaluate the effect of calcium channel blockers on hypertensive patients with obstructive sleep apnea(OSA), and the other is to assess the effect of Chinese medicine on OSA. The two systemic reviews are of the same methods:Databases of CNKI、CBM、VIP、MEDLINE、Embase、CDSR、CCTR were searched for all available data till January 2011. RevMan 5 software was used to conduct meta-analysis. GRADE profiler was used to assess the quality of the included trials.
2.2 Clinical trial of Qingxuan granule
This study is a stratified, randomized, doubled-blind, placebo-controlled clinical trial.
2.2.1 90 mild and moderate hypertensive patients with Yin deficiency and Yang hyperactivity syndrome were enrolled into the study. Each one received portable sleep monitoring,24hour Ambulatory Blood Pressure monitoring(ABPM), and blood pressure mean values, blood pressure variability(BPV), blood pressure circadian rhythm and obstructive sleep apnea(OSA) were collected and their correlation was analyzed:endothelial function was evaluated by flow-mediated dilation (FMD), also nitric oxide/endothelin-1(NO/ET-1)、high-sensitivity C-reactive protein(hs-CRP)、and rein-angiotensin-aldosterone system (RAAS) were tested to explore the functional mechanism. Stepwise regression was used to analyze the correlation of OSA,blood pressure and endothelial function.
2.2.2 According to the OSA diagnosis, the hypertensive patients were assigned into two subgroups, one with OSA, the other without OSA; and in each subgroup, patients were randomized into treatment group and control group. All of the patients were treated by amlodpine, in addition, Qingxuan granule was given to the treatment group, and placebo was given to the control goup, respectively. After 2months treatment, the difference (D-value) of the blood pressure, endothelial and OSA index between pretreatment and post-treatment were analyzed by covariance analysis in generalized linear model, so as to investigate the treatment effects of Qingxuan granule, and the impacts of OS A on the D-value in these patients.
3 Results
3.1 Results of systematic review
3.1.1 The effect of calcium channel blockers on hypertensive patients with obstructive sleep apnea(OSA), a Meta-analysis.
Compared with control group, though not statistically significance, calcium channel blockers shows a tendency to improve systolic pressure(SBP), diastolic pressure(DBP), (P>0.05) Heart rate was significantly lower after the treatment with calcium channel blockers than the control group; and no significant difference was found in total sleep time, sleep efficiency, deep sleep, and REM stage sleep between these two groups (P>0.05). According to GRADE, the quality of all the results was low or very low.
3.1.2 The effect of Chinese medicine on OS A patients, a Meta-analysis. Compared with conventional western treatment, the addition of Chinese medicine could significantly improve the OSA patients'total sleep time, hypopnea index(HI), total hypopnea time, the time of desaturation less than 90% (P<0.05). No significant difference was found in improving clinical efficiency, apnea index(AI), the numbers of times of desaturation less than 90%,mean heart rate (P>0.05). According to GRADE, the quality of all the results was low or very low.
The results of clinical trials
3.2.1 Comparison of blood pressure between hypertensive patients with OSA and without OSA The blood pressure variability and the occurrence of non-dipper hypertension were significantly higher in hypertensive patients with OSA than those without OSA, while night time blood pressure fall rate was significantly lower in patients with OSA than those without OSA. (P<0.05). AHI had positive correlation with night time SBP and 24 hour SBP SD, and negative correlation with night time SBP fall rate (P<0.05)
3.2.2 Comparison of endothelial function between hypertensive patients with OSA and those without OSA
FMD%,NO,NO/ET were significantly lower in hypertensive patients with OSA than those without OSA, while ET-1、PRA、A ngⅡ、ALD were significantly higher in patients with OSA than those without OSA (P<0.05); AHI had positive correlation with PRA and AngⅡ, and negative correlation with NO/ET ratio (P<0.05)
3.2.3 Analysis of Qingxuan granule's curative effect on hypertensive patients with and without OSA
3.2.3.1 Analysis of curative effect on treatment group and control group for all patients
After subtracting the interference from OSA and index'baseline levels, the following indexes' declined more in treatment group than in control group (P(a)<0.05):24hSBP SD、daytime SBP SD、night time SBP SD、24hDBP SD、24hDBP CV、daytime DBP SD、night time DBP SD、heart rate、ET、AngⅡ; and the following indexes increased more in treatment group than control group (P(a)<0.05):FMD and NO/ET ratio. 3.2.3.2 Impacts of OSA on curative effect
After filtering out the interference from different treatments and index'baseline levels, the following indexes declined less in patients with OSA than those without OSA:night time SBP、24hSBP SD、daytimeSBP SD、night timeSBP SD、24hDBP SD、24hDBP CV、daytimeDBP SD、night time DBP SD、night time DBP CV、heart rate、hs-CRP、PRA、AngⅡ、ALD; and the following indexes increased less in patients with OSA than those without OSA:night time SBP fall rate, night time DBP fall rate, FMD,NO,NO/ET ratio.
3.2.3.3 Analysis of subgroup
In hypertensive patients with OSA,the following indexes declined more in treatment group than control group:24hSBP SD、24hDBP SD、daytimeSBP SD、daytimeDBP SD、night timeSBP SD、night time DBP SD、AngⅡ(P<0.05); and the following indexes increased more in treatment group than control group:NO/ET ratio (P<0.05)
In hypertensive patients without OSA, the following indexes declined more in treatment group than control group:24hSBP SD、24hDBP CV、daytimeSBP SD、daytimeDBP SD、night time DBP SD、ET-1、hs-CRP、AngⅡ; and the following indexes increased more in treatment group than control group:FMD、NO/ET ratio (P<0.05)
3.2.3.4 Impact of Qingxuan granule on OSA
No significant difference was found in OSA' index after taking Qingxuan granule (P>0.05), with the exception that HI decreased and hypopnea improved (P<0.05)
4 Conclusions
4.1 The result of systematic review suggest that calcium channel blockers is not superior to control group in improving blood pressure level and OSA (P>0.05), while Chinese medicine could improve OSA to a certain extent (P<0.05); a large number of high quality researches are still needed to prove this result.
4.2 In hypertensive patients with OSA the blood pressure variability increased, circadian rhythm was out of order; the endothelial relaxing and contracting function, inflammatory reaction, and RAAS were not normal; OSA could also weaken the curative effect of hypotensive drugs on these indexes.
4.3 For hypertensive patients, Qingxuan granule could improve the blood pressure variability, promote the recovery of endothelial function, balance the endothelial relaxing and contracting ratio, control the excessive increase of AngⅡ; also Qingxuan granule could help to decrease the hypopnea index in OSA, and further study is needed to verify this result.
引文
[1]Chobanian AV, Bakris GL, Black HR, et,al.The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA,2003,289 (19):2560-2572.
[2]王文,王增武,陈伟伟.我国高血压防治的关键在基层.中华高血压杂志,2010,18(6)：501-503.
[3]Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S:The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med,1993, 328:1230-1235.
[4]Lavie P, Ben Yousef R,Rubin AE. Prevalence of sleep apnea syndrome among patients with essential hypertension. Am Heart J,1984,108:373-376.
[5]Peppard PE, Young T, Palta M & Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. NEngl J Med,2000,342, 1378 1384.
[6]Mohsenin V, Yaggi HK, Shah N, Dziura J. The effect of gender on the prevalence of hypertension in obstructive sleep apnea. Sleep Med,2009,10(7):759-762.
[7]Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease:an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing.J Am Coll Cardiol.2008,52 (8):686-717.
[8]Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension,2003,42:1206-1252.
[9]张京春,陈可冀.关于美国JNC-7高血压指南的评述.中国中西医结合杂志,2003,23(10)：724-726.
[10]Gonz a lez Bosc LV, Resta T, Walker B, Kanagy NL. Mechanisms of intermittent hypoxia-induced hypertension. J Cell Mol Med,2009, Oct 10.
[11]Atkeson A, Yeh SY, Malhotra A, Jelic S. Endothelial function in obstructive sleep apnea. Prog Cardiovasc Dis,2009,51 (5):351-362.
[12]Das AM, Khayat R. Hypertension in obstructive sleep apnea:risk and therapy. Expert Rev Cardiovasc Ther,2009,7 (6):619-626.
[13]Butt M, Dwivedi G, Khair O, Lip GY. Obstructive sleep apnea and cardiovascular disease. Int J Cardiol,2009, Jun 6.
[14]Gjφrup PH, Hedner J. Hypertension and obstructive sleep apnoea. Ugeskr Laeger, 2009,171 (25):2091-2094.
[15]Devulapally K, Pongonis R Jr, Khayat R. OSA:the new cardiovascular disease: part Ⅱ:Overview of cardiovascular diseases associated with obstructive sleep apnea.Heart Fail Rev,2009,14 (3):155-164.
[16]Dopp JM, Reichmuth KJ, Morgan BJ. Obstructive sleep apnea and hypertension: mechanisms, evaluation, and management. Curr Hypertens Rep,2007,9 (6):529-34.
[17]Hoffmann M, Bybee K, Accurso V, Somers VK. Sleep apnea and hypertension. Minerva Med,2004,95 (4):281-290.
[18]Weiss JW, Liu MD, Huang J. Physiological basis for a causal relationship of obstructive sleep apnoea to hypertension. Exp Physiol,2007,92 (1):21-26.
[19]Cooper VL, Elliott MW, Pearson SB, Taylor CM, Mohammed MM, Hainsworth R. Daytime variability of baroreflex function in patients with obstructive sleep apnoea:implications for hypertension. Exp Physiol,2007,92 (2):391-398.
[20]Ziegler M G, Mills PJ, Loredo JS, et al. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest,2000,120:887-893.
[21]Vanninen E,Tuunainen M,Kansanen M, et al. Cardiac sympatho2 vagal balance during sleep apnea episodes. Clin Physiol,1996,16 (3):209.
[22]Coy TV, Dimsdale J E, Ancol i-Israel S, et al. Sleep apnea and sympathelic nervous system activety. J Sleep Res,1996,5 (1):42.
[23]罗荧荃,黄国庆,杨宇.慢性间歇低氧诱发大鼠高血压模型的建立.中国新药杂志,2006 15(22)：1930-1933.
[24]袁志明,陈宝元,王佩显,蒋汉涛,张敬霞.慢性间歇低氧诱发大鼠高血压发病过程中一氧化氮和一氧化氮合酶的变化.J Clin Cardiol (China),2005,21(8):472-475.
[25]Gonz a lez-Martin MC, Vega-Agapito V, Prieto-Lloret J, Agapito MT, Castaneda J, Gonzalez CAdv Exp Med Biol. Effects of intermittent hypoxia on blood gases plasma catecholamine and blood pressure,2009,648:319-328.
[26]Gard:-Rio F, Racionero MA, Pino JM, et al. Sleep and hypertension. Chest, 2000,117(5):1414-1425.
[27]Yoon IY, Jeong DU. Degree of arousal is most correlated with blood pressure reactivity during sleep in obstructive sleep apnea. J Korean Med Sci 2001,16:707-711.
[28]钟旭,肖毅.降压药对于阻塞性睡眠呼吸暂停低通气综合征患者相关动脉血管反应的作用.中华结核和呼吸杂志,2005,28(6)：377-381.
[41]杜以明,薛玉文.OSAHS合并高血压与血浆内皮素关系的研究.新医学,2007,38(3)：171-173.
[42]王廷础,卢红霞,王欣,王岩,张丙峰.阻塞性睡眠呼吸暂停低通气综合征合并高血压患者睡眠结构分析及血清内皮素-1的测定.中华耳鼻咽喉科杂志,2004,39(2)：55-58.
[43]陈瑀.内皮素与阻塞性睡眠呼吸暂停低通气综合征所致高血压的相关性探讨(附48例分析).福建医药杂志,2010年,32(3)：22-23.
[44]陈光辉,王士雯,张文莉,王莉,盖鲁粤.血管活性物质在睡眠呼吸暂停综合征合并高血压中作用的研究.解放军医学杂志,2006,31(2)：147-149.
[45]王国付,钦光跃,吴健,吴金彦,顾亮.阻塞性睡眠呼吸暂停低通气综合征血管内皮细胞功能的研究中国实用内科杂志,2006,26(21)：1709-1711.
[46]马秀芬,平芬,刘美霞,凌亦凌.血栓素A2、前列环素与阻塞性睡眠呼吸暂停低通气综合征及其合并高血压的相关性研究.《临床荟萃》,2005,20(24)：1396-1399.
[47]Baylor P,Mouton A, Shamoon HH, et al. Increased norepinephrinevariability in patients with sleep apnea syndrome. AmJ Med,1995,99 (6):611.
[48]Gibbons GH, Deanfield J, Donald A, Ferri C1, et. Endothelial function as a determinant of vascular function and structure:a new therapeutic target. Am J Cardiol 1997,79:3 873.
[49]Moller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens,2003,274 280.
[50]陈光辉,王士雯,张文莉,王莉,易军.睡眠呼吸暂停综合征对部分心血管活性物质变化的影响.军医进修学院学报,2005,26(2)：137.
[51]Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivates in obstructive sleep apnoea; response to CPAP therapy. Thorax,2000, 55:1046 1051.
[52]杨朝,张锦.阻塞性睡眠呼吸暂停低通气综合征患者血浆ET-1、NO水平的变化及nCPAP对其影响.中国老年学杂志,2004,24(9)：793-795,
[53]苏红,陈学远,张建全,李国秀,邓静敏.阻塞性睡眠呼吸暂停低通气综合征血管活性物质失衡的研究.广西医科大学学报,2004,21(3)：30-33.
[54]BOULANGER C M. Secondary endothelial dysfunction:hypertension and heart-failure [J]. J Mol Cell Cardiol,1999,31:39-49.
[55]DEAM R T, WILCOX I. Possible at herogenic effect s of hypoxia during obstructive sleep apnea [J]. Sleep,1993,16 (8):15-21.
[56]薛静,汪贺媛,孙磊,李立新,高仲群,黄舒.OSAHS合并高血压患者内皮素和降钙素基因相关肽检测.中国耳鼻咽喉头颈外科,2005,12(6)：47-49.
[57]Phillips CL, Yang Q, Williams A, Roth M, Yee BJ, Hedner JA, Berend N, Grunstein RR. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnoea. J Sleep Res,2007,16 (2):217-225.
[58]窦晓辉,曾亮,汪志伟.阻塞性睡眠呼吸暂停低通气综合征患者炎症因子水平变化.中国耳鼻咽喉头颈外科,2007,14(5)：76-78.
[59]牛红丽,马利军,王海播,况红艳.OSAHS合并高血压患者血清炎症因子浓度与血压的关系.中国实用医药,2008,30期
[60]张黎军,刘淑华,刘昌慧,刘涓.阻塞性睡眠呼吸暂停低通气综合征患者细胞粘附分子水平的研究.微循环学杂志,2005,04期
[61]康健,王赞峰.炎症、氧化应激与阻塞性睡眠呼吸暂停低通气综合征.中华结核和呼吸杂志,2006,29(4)：226-227.
[62]龙利民,杨宇,黄国庆.固性高血压合并OSAHS患者nCPAP治疗前后血压与血清高敏C反应蛋白水平的研究.中国医师杂志,2006,8(10)：1352-1354.
[63]刘志.老年高血压病发阻塞性睡眠呼吸暂停综合征患者血压特点及与炎症因子的关系.心脏杂志,2008,20(5)：574-587.
[64]Riha RL, Brander P, Vennelle M, et al. Tumour necrosis factor2a (2308) gene polymorphism in obstructive sleep apnoea2hypopnoea syndrome [J]. Eur Respir J,2005,26(4):673-678.
[65]魏建军,张希龙,李翀.阻塞性睡眠呼吸暂停低通气综合征患者炎症因子与高血压的相关性.内科理论与实践,2009,4(5)：404-407.
[66]张敏艳.阻塞性睡眠呼吸暂停低通气综合征与白细胞介素-6关系的临床研究.山西医药杂志,2008,37(2)：164-165.
[67]李艳,温雪萍,陈学奎,颜志军,王忠慧.阻塞性睡眠呼吸暂停综合征免疫网络及其与临床的相关性.中国医师进修杂志,2006,29(8)：19-20.
[68]李延忠,张万荣,王廷础,卢红霞,王岩,王欣.粘附分子在阻塞性睡眠呼吸暂停低通气综合征合并高血压发病中的作用.中华结核和呼吸杂志,2007,27(8)：511-514.
[69]Schulz R, Hummel C, Heinemam S, et al. Serum levels of vascular endothelial growth factor and elevated in patients with obstructive sleep apnea and severe night time hypoxia[J]. Am J Respir Crit Care Med,2002,165(1):67-70.
[70]Teramoto S, Kume H, Yamamoto H, et al. Effects of oxygen administration on the circulating vascular endothelial growth factor (VEGF) levelsin patients with obstructive sleep apne syndrome [J]. Intern Med,2003,42(8):681-685.
[71]Takekoshi K, Ishii K, Nanmoku T, Shibuya S, Kawakami Y, Isobe K, Nakai T. Leptin stimulates catecholamine synthesis in a PKC-dependent manner in cultured porcine adrenal medullary chromaffin cells. Endocrinology,2001,142 (11):4861-4871.
[72]吕昌惠,郭宜,崔淑芬.阻塞性睡眠呼吸暂停低通气综合征患者血清瘦素水平的研究.中国综合临床,2006,22(9)：780-783.
[73]张健,叶珏,裴卫东,格桑罗布,惠汝太,刘力生.不同程度阻塞性睡眠呼吸暂停合并高血压与血管紧张素转换酶基因多态性的比较研究.血压杂志,2000,8(2)：129-131.
[74]Koyama RG, Drager LF, Lorenzi-Filho G, Cintra FD, Pereira AC, Poyares D, Krieger JE, Castro RM, Tufik S, de MelloMT, Pedrazzoli M. Reciprocal interactions of obstructive sleep apnea and hypertension associated with ACE I/D polymorphism in males. Sleep Med,2009,22.
[75]Bostrom KB, Hedner J, Melander 0, Grote L, Gullberg B, Rastam L, Groop L, Lindblad U. Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension. J Hypertens,2007,25 (4):779-783.
[76]李延忠,张万荣,王廷础,卢红霞,王欣,王岩.OSAHS并发高血压患者血管紧张素转换酶基因多态性及血清血管紧张素Ⅱ水平测定.J Clin Otorhinolaryngol, 2004,18(8)：11-14.
[77]黄蓉,黄席珍,黎明,肖毅,张健.瘦素受体基因G1n223Arg多态性与阻塞性睡眠呼吸暂停低通气综合征的关系.中华结核和呼吸杂志,2003,26(9)：517-519.
[78]王胜国,周本忠,孙敬武,胡勇,李皓,兰兰.阻塞性睡眠呼吸暂停低通气综合征患者咽部组织中瘦素受体表达的初步研究.中华耳鼻咽喉头颈外科杂志,2005,40(10)：787-788.
[79]岳伟华,刘破资,郝伟,张向晖,王小平,张纪水,周旭辉,谢永标,倪明.睡眠呼吸暂停综合征与5-羟色胺转运体基因多态性的关联分析.中华医学遗传学杂志,2005,22(5)：533-535.
[80]阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案).中华医学会呼吸病学分会睡眠呼吸疾病学组,2001年.
[81]孙书臣,刘艳骄.多导睡眠仪实用技术手册.人民军医出版社.
[82]Lavie-Nevo K, Pillar G. Evening-morning differences in blood pressure in sleep apnea syndrome:effect of gender. A m J Hyper tens,2006,19 (10):1064-9.
[83]童茂荣.多导睡眠图学技术与理论.人民军医出版社,7.
[84]Chan AS, Phillips CL, Cistulli PA. Obstructive sleep apnoea-an update. Intern Med J,2009,7.
[85]Zou D, Grote L, Peker Y, Lindblad U, Hedner J. Validation a portable monitoring device for sleep apnea diagnosis in a population based cohort using synchronized home polysomnography. Sleep,2006,29 (3):367-374.
[86]林其昌,陈公平,丁海波,邓朝胜,王春娥.持续气道正压通气治疗老年人阻塞性睡眠呼吸暂停低通气综合征合并高血压的疗效.中华老年医学杂志,2005,24(8)：595-597.
[87]赵军,郝芙蓉,汪贺媛,魏小刚.经鼻持续气道正压通气治疗睡眠呼吸暂停综合征合并高血压的临床研究.《临床荟萃》,2008,23(15)：1084-1085.
[88]徐江祥,刘志强,黄小红,胡星兰,王霞,夏斌,曹玲玲,蔡平,汤杰,徐保朝,余达训.气道正压通气治疗高血压伴阻塞性睡眠呼吸暂停低通气综合征.中华高血压杂志,2007,15(1)：49-52.
[89]李莉,吴海英,刘力生.睡眠呼吸暂停综合征与高血压治疗.中华心血管病杂志,2004,32(1)：30-32.
[90]秦淑辉,封彦凤,吕志平,肖文良.阻塞性睡眠呼吸暂停低通气综合征合并高血压的治疗.《临床荟萃》,2009,24(8)：697-699.
[91]黎燕群,张希龙.持续气道正压通气治疗对阻塞性睡眠呼吸暂停综合征患者难治性高血压的影响.南京医科大学学报(自然科学版),2008,28(2)：210-214.
[92]Norman D, Loredo JS, Nelesen RA, Ancoli-Israel S, Mills PJ, Ziegler MG, Dimsdale JE. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. H ypertension, 2006,47 (5):840-845.
[93]Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension,2007,50 (2):417-423.
[94]Middleton S, Vermeulen W, Byth K, Sullivan CE, Middleton PG.Treatment of obstructive sleep apnoea in Samoa progressively reduces daytime blood pressure over 6 months. Respirology,2009,14 (3):404-410.
[95]Lattimore JL, Wilcox I, Skilton M, Langenfeld M, Celermajer DS. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax,2006,61 (6):491-495.
[96]Tun Y, Hida W, Okabe S, Ogawa H, Kikuchi Y, Oikawa M, Kitamuro T, Kunio S. Can nasal continuous positive airway pressure decrease clinic blood pressure in patients with obstructive sleep apnea? Tohoku J Exp Med,2003,201 (3):181-190.
[97]Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients.Eur Respir J,2006,27 (6):1229-1235.
[98]Hermida RC, Zamarron C, Ayala DE, Calvo C. Effect of continuous positive airway pressure on ambulatory blood pressure in patients with obstructive sleep apnoea. Blood Press Monit,2004,9 (4):193-202.
[99]Kim JH, Kwon MS, Song HM, Lee BJ, Jang YJ, Chung YS. Compliance with positive airway pressure treatment for obstructive sleep apnea. Clin Exp Otorhinolaryngol, 2009,2 (2):90-96.
[100]弓艳辉,明彦,杨伟国.高血压患者合并阻塞性睡眠呼吸暂停低通气综合征正压通气与外科治疗对血压的影响.中国老年学杂志,2008,28(4)：811-812.
[101]Andr e n A, Sjoquist M, Tegelberg A. Effects on blood pressure after treatment of obstructive sleep apnoea with a mandibular advancement appliance-a three-year follow-up. J Oral Rehabil,2009,36(10):719-725.
[102]李惠兰,李瑛,王蓓,闫学军,刘瑛年,宋满景.口腔矫治器治疗阻塞性睡眠呼吸暂停综合征型高血压老年患者疗效观察.中华结核和呼吸杂志,2001,24(3)：180.
[103]霍艳明,李丹,王薇,丁烈,李明贤,马英明,王辉奇,于洁,孙伟.高血压病合并睡眠呼吸暂停低通气综合征的临床研究.中国医药指南,2010,8(30)：14-15.
[104]王蕾.高血压合并阻塞性睡眠呼吸暂停低通气综合征中医证候的临床研究.2010年,南京中医药大学硕士学位论文.
[105]田华,李晓兵,霍素婷.断调波治疗睡眠呼吸暂停综合征合并高血压病的临床研究. 河北中医,2007,29(5)：397-436.
[1061粟俊,李磊,钟力平.黄连温胆汤治疗睡眠低通气的临床研究.中医药临床杂志,2004,16(5)：423-424.
[107]郭湘芳,粟俊,吕晶.通塞消栓汤治疗脑梗死兼阻塞性睡眠呼吸暂停低通气综合征30例.中国中医药信息杂志,2007,14(6)：13-14.
[108]粟俊,李磊,钟力平,邓映辉.升陷汤联合都可喜治疗阻塞性睡眠呼吸暂停低通气综合征38例临床观察.中医杂志,2010,(7)：600-602.
[109]关风岭,关思友.自拟桔梗愈鼾汤治疗睡眠呼吸暂停综合征20例临床研究.四川中医,2005,23(12)：49-50.
[110]杨水清,朱斯洪.自拟化痰理气汤治疗阻塞性睡眠呼吸暂停低通气综合征疗效观察.中医药临床杂志,2006,18(2)：146-147.
[111]胡良冈,徐晓梅,王良兴,龚永生,范小芳,王胜初.经皮电刺激治疗阻塞性睡眠呼吸暂停综合征的研究.中国生物医学工程学报,2005,24(3)：370-373.
[112]王晓红,肖兰英,王保法,袁雅冬,潘文森,石玉珍.耳穴贴压疗法对阻塞性睡眠呼吸暂停综合征患者睡眠结构的影响.中医杂志,2006,47(8)：584-586.
[113]陈敏,江学勤,陈利华.针刺治疗阻塞性睡眠呼吸暂停综合征的临床研究.四川中医.2005,23(10)：104-105.
[114]Hedner J, Grote L, Zou D. Pharmacological treatment of sleep apnea:current situation and future strategies.Sleep Med Rev.2008,12(1):33-47.
[115]Pack AI, Gislason T. Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis,2009,51 (5):434-451.
[116]Bradley TD, Floras JS, Obstructive sleep apnoea and its cardiovascular consequences. Lancet,2009,373(9657):82-93.
[117]张健,谢晋湘,惠汝太,柳志红,刘力生.阿罗洛尔降压疗效和对睡眠呼吸障碍的影响.中国循环杂志,1998,13(6)：331-333.
[118]陈明,孙雷.伴有阻塞性睡眠呼吸暂停综合征高血压患者的夜间药物降压对策.江苏医药,2006,32(9)：862-863.
[119]平芬,李贤,苏力,高凤岐,赵景春,韩书芝,田蓉.海捷亚对阻塞性睡眠呼吸暂停低通气综合征合并高血压患者降压疗效和睡眠呼吸的影响.中国老年学杂志,2005,25(9)：1030-1032.
[120]张健,谢晋湘,惠汝太,许玉春,龚维如,汪芳,李莉,李天德,邓开伯,刘力生.赖诺普利治疗原发性高血压及其合并睡眠呼吸暂停的临床试验.高血压杂志,1998,6(4)：257-259.
[121]李莉,谢晋湘,李喜梅,张彬,丁昌玲,刘力生.抑平舒的降压效果和对睡眠呼吸障碍的影响.高血压杂志,1999,7(4)：343-346.
[122]HOLGER KRAICZI, JAN HEDNER, YUKSEL PEKER, and LUDGER GROTE. Comparison of Atenolol, Amlodipine, Enalapril,Hydrochlorothiazide, and Losartan for Antihypertensive Treatment in Patients with Obstructive Sleep Apnea. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,2000:1423-1428.
[123]Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D.Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol,2009,53 (15):1309-1317.
[124]Okcay A, Somers VK, Caples SM. Obstructive sleep apnea and hypertension. J Clin Hyper tens (Greenwich),2008,10(7):549-555.
[1]陈懿宇,张京春.高血压血管内皮机制的中西医研究现状.中国老年学杂志,2010,20(30)：3010-3013.
[2]Gkaliagkousi E, Douma S, Zamboulis C, Ferro A. Nitric oxide dysfunction in vascular endothelium and platelets:role in essential hypertension. J Hypertens, 2009,27(12):2310-20.
[3]Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C. Essential hypertension:is there a role for inflammatory mechanisms? Cardiol Rev,2009,17 (5):216-21.
[4]陈明,胡申江,张健,等.不同危险度的高血压人血管内皮功能.高血压杂志,2006,14(4)：257-260.
[5]de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens, 2010,24(6):373-9.
[6]李卫萍,孙明,周宏研,等.原发性高血压患者血管内皮功能失调与活性氧的关系及阿托他汀治疗的影响[J].中国现代医学杂志,2005,15(7)：1096-1103.
[7]李小兵,冼绍祥,洪永敦.高血压病证候与内皮功能失调及自由基损伤的关系探讨.中国中医基础医学杂志,2005,11(5)：62-364.
[8]Rossi R, Chiurlia E,Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women [J]. J Am Coll Cardiol,2004,44 (8):1636-1640.
[9]Suwaidi J, Hamasaki S, H igano S, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation,2000, 101:948-954.
[10]Gokce N, Keaney JF J r, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function:a prospective study. Circulation,2002,105:1567-1572.
[11]Shimizu Y, Nagaya N,Teranishi Y,et al.Ghrenlin improves endothelial dysfunction through growth hormone independent mechanisms in rats [J].Biochem Biophys Res Comm un,2003,310 (3):830.
[12]Li GZ,Jing W,Zhao J, et al.Ghrelin blunted vascular calcification in vivo and in vitro in rats[J]. Regul Pept,2005,129 (1):167.
[13]Nakamura T, Mizuno S,Matsumoto K, et al. Myocardial protection from ischemia Preperfusion injury by endogenous and exogenous HGF. J Clin Invest,2000,106 (12):1511-1519.
[14]Makin AJ,Blann AD, Chung NA, et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor [J]. Eur Heart J,2004,25 (5):371-376.
[15]Jimenez JJ, Jy W,Mauro L, et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura (TTP):findings from brain and renal microvascular cell culture and patients with active disease [J].Br J Haematol,2001,112:81-90.
[16]王妍,陶军,涂昌,陈龙,杨震,徐明国,王洁梅,黄奕俊.高血压患者循环内皮细胞微颗粒水平的变化.中华老年心脑血管病杂志,2006,8(4)：222-224.
[17]de la Pena M, Barcel o A, Barbe F, et al. Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration,2008,76(1):28-32.
[18]周丽娜,余毅,吴可贵.心血管疾病氧化应激对内皮祖细胞的影响.中华高血压杂志2007,15(11)：893-895.
[19]Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery:a report of the International Brachial Artery Reactivity Task Force [J]. J Am Coll Cardiol,2002,39(2):257-265.
[20]孙妍,王国干,沈磊,等.高血压患者血管内皮功能及颈动脉内-中膜厚度与冠心病事件关系的研究.中国超声医学杂志,2007,23(12)：908-910.
[21]Tio RA,Monnink SH,Amoroso G, et al. Safety evaluation of routine intracoronary acetylcholine infusion in patients undergoing a first diagnostic coronary angiogram [J]. J Investig Med,2002,50 (2):133-139.
[22]Kjaer A,Meyer C, Nielsen FS, et al. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction:a PET study of myocardial perfusion in diabetes [J].J Nucl Med,2003,44 (1):19-23.
[23]Modena M, Bonetti L, Coooi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. Jam Coll Cardiol,2002,40: 505-5101.
[24]黄震华.抗高血压药物与血管内皮功能.中国新药与临床杂志,2005,5(24)：398-401.
[25]TADDEI S, V IRD IS A, GH IADON IL, et al. Effects of antihypertensive drugs on endothelial dysfunction:clinical implications [J]. Drugs,2002,62 (2) 265-284.
[26]宋月霞,王希柱,钟雪莲.非洛地平对高血压患者血浆生长素水平和血管内皮功能的影响.中国药房,2007,18(20)：1572-1573.
[27]MU IESAN ML, SALVETTIM, MONTEDURO C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension [J]. Hypertension,1999,33(2):575-580.
[28]吕纳强,何苒,宋卫华,党爱民.伊贝沙坦对原发性高血压患者血浆内皮素及循环内皮细胞的影响.中华高血压杂志,2007,15(6)：465-467.
[29]Tzemos N,Lim PO,MacDonald TM.Valsartan improves endothelial dysfunction in hypertension:a randomized,double-blind study[J]. Cardiovasc Ther,2009, 27(3):151-8.
[30]Galiavich AS, Khamidullina AR, Galiavich RA. Effect of antihypertensive drugs on some humoral parameters of endothelial function[J]. Kardiologiia,2009,49 (5): 30-3.
[31]刘妙,萧佩玉.苯那普利对原发性高血压患者内皮功能和血清细胞因子水平的影响.中山大学学报,2007,28(6)：215-217.
[32]Sozen AB, Kayacan MS, Tansel T, Celebi A, Kudat H, Akkaya V, Erk 0, Hatipoglu I, Demirel S. Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. J Int Med Res.2009,37(4):996-1002.
[33]Musikhina NA, Iuferova OV, Gapon LI, Makhneva EA, Belikova EA, Petelina TI, Todosi□chuk VV. Structural-functional properties of the vascular wall in hypertensive patients with coronary heart disease:effects of felodipin and perindopril. Ter Arkh.2009,81 (9):13-6.
[34]Family Practice News,2007-04-12.顽固性高血压治疗新药-内皮素受体拮抗剂.中华高血压杂志,2007,15(5),436.
[35]张臣,邢之华,刘卫平,冯雪辉,蔡昌龙,谭海彦.高血压病中医证型与血浆内皮素及血压的相关性研究.辽宁中医杂志2005,32(1)：6-7.
[36]谭海彦,朱莉,邢之华,刘卫平,蔡昌龙,张臣.天麻钩藤饮改善高血压患者内皮功能的机理研究.山东医药,2005,45(1)：12-13.
[37]王书梅,刘建.天麻钩藤饮对66例高血压患者一氧化氮和内皮素影响的临床研究.现代预防医学,2006,33(6)：1052-1053.
[38]林展增,邢之华,蔡昌龙,谭海彦,张臣.天麻钩藤饮对肝阳上亢型原发性高血压患者血浆内皮素的影响.中国临床康复,2004,8(27)：5992-5993.
[39]张焱,陈咸川,何立人,童仙君,黄薇.化湿利水泄浊合剂对高血压病患者血管内皮依赖性舒张功能的影响.上海中医药杂志,2005,39(6)：14-16.
[40]杜立峰,杨杰,孙师元,王小闯,吴喜利.平肝降压胶囊对原发性高血压患者血浆内皮素和血管紧张素Ⅱ的影响.中国临床康复,8(36)：8250-8251.
[41]卢全生.清眩胶囊治疗轻中度高血压病的实验和临床研究.中国中医研究院博士学位论文,2003.
[42]谢元华,张京春,蒋跃绒,等.陈可冀辨治高血压病医案的数据挖掘分析.中西医结合心脑血管病杂志,2008,6(2)：135-136.
[43]刘婷,张毅,秦彩玲,孙玉茹.桂枝汤降压作用机制初探——对血浆及组织中ET、NT含量的影响。中国药学杂志,2005,3(40)：421-423.
[44]徐树楠,张再康,冯瑞雪,刘海丽,张凯.活血降压方对自发性高血压大鼠血压及血浆ET、血清NO含量的影响.中药药理与临床,2004,20(5)：39-40.
[45]徐树楠,侯仙明,王文智,贾云芳.潜阳通络方对肝阳上亢型高血压病大鼠血压和ET、ANP的影响.中国中医基础医学杂志,2007,13(12)：908-909.
[46]李景新,王贞,王蓉,刘克敬,陈连璧.沙苑子总黄酮对自发性高血压大鼠血脂及内皮素活性的影响.中国微循环,2004,8(5)：336-337.
[47]金龙,周文泉.络活胶囊治疗高血压病的实验研究.中国中西医结合杂志,2004,24：18-20.
[48]陈双厚,刘瑞华,李世洁.降压舒心胶囊对实验肾性高血压大鼠血清内皮素、血浆血管紧张素Ⅰ、Ⅱ含量的影响.中药药理与临床,2004,20(3)：28-29.
[49]赵萍,陈洁,洪永敦,曾燕静.温胆泄浊法对痰浊型高血压病患者血管内皮舒张功能与粥样硬化改善作用的超声研究.中国中西医结合杂志,2007,27(1)：21-24.
[50]王晓君,黄文增,张步延.联服川芎素、培哚普利与单服培哚普利对高血压患者血管内皮功能和血压的影响.中华高血压杂志,2006,14(12)：993-996.
[51]李浩,郭明冬,刘剑刚.降压胶囊联合尼莫地平对自发性高血压大鼠ET、CGRP及AngⅡ水平的影响.中国老年学杂志,2007,27：2178-2180.
[1]Fletcher, E. C., R. D. DeBehnke, M. S. Lovoi, and A. B. Gorin. Undiagnosed sleep apnea in patients with essential hypertension.Ann. Intern. Med.1985,103:190-195.
[2]Olson, L. G., M. T. King, M. J. Hensley, and N. A. Saunders. A community study of snoring and sleep-disordered breathing:health outcomes. Am. J. Respir. Crit. Care Med. 1995,152:717-720.
[3]Rauscher, H., D. Formanek, W. Popp, and H. Zwick. Nasal CPAP and weight loss in hypertensive patients with obstructive sleep apnoea. Thorax.1993,48:529-533.
[4]McArdle, N., G. Devereux, H. Heidarnejad, H. M. Engleman, T. W. Mackay, and N. J. Douglas. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am. J. Respir. Crit. Care Med.1999,159:1108-1114.
[5]I. Kantola, E.Rauhala, M. Erkinjuntti, L Mansury. Sleep disturbances in hypertension:A double-blind study between isradipine and metoprolol. Journal of Cardiovascular Pharmacology.1991,18(1):41-45.
[6]J Heitmann, L Grote, L. Knaack. U Kohler. M. Hinder, JH Peter.. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea. Eur J Clin Pharmacol. 1998,54:691-696.
[7]Bartel P.R, Loock M, Becker P. Short-term antihypertensive medication does not exacerbate sleep-disordered breathing in newly diagnosed hypertensive patients. American Journal of Hypertension.1997,10(6):640-645.
[1]阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案).中华医学会呼吸病学分会睡眠呼吸疾病学组,2001年。
[2]. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5 (2):136-143.
[3]McArdle, N., G. Devereux, H. Heidarnejad, H. M. Engleman, T. W. Mackay, and N. J. Douglas. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am. J. Respir. Crit. Care Med.1999,159:1108 1114.
[4]粟俊,李磊,钟力平.黄连温胆汤治疗睡眠低通气的临床研究.中医药临床杂志,2004,16(5)423-424.
[5]郭湘芳,粟俊,吕晶.通塞消栓汤治疗脑梗死兼阻塞性睡眠呼吸暂停低通气综合征30例.中国中医药信息杂志,2007,14(6)13-14.
[6]粟俊,李磊,钟力平,邓映辉.升陷汤联合都可喜治疗阻塞性睡眠呼吸暂停低通气综合征38例临床观察.中医杂志,2010,(7)600-602.
[7]关风岭,关思友.自拟桔梗愈鼾汤治疗睡眠呼吸暂停综合征20例临床研究.四川中医,2005,23(12)49-50.
[8]杨水清,朱斯洪.自拟化痰理气汤治疗阻塞性睡眠呼吸暂停低通气综合征疗效观察.中医药临床杂志,2006,18(2)146-147.
[9]广东省卫生厅编印.广东省常见病基本诊疗规范.第一册,内部材料,1998,39-41
[1]Whitworth JA,World Health Organization, International Society of Hypertension Writing Group.2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension(Guidelines and recommendations). J Hypertens,2003,21:1983-1992.
[2]中华人民共和国卫生部.中国高血压防治指南(2005年修订版).2005.
[3]郑筱萸.中药新药临床研究指导原则.北京：中国医药科技出版社,2002：73-77.
[4]中华医学会呼吸病学分会睡眠呼吸疾病学组.阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案)[J].中华结核和呼吸杂志,2002,25(3)：195-198.
[5]睡眠呼吸暂停与心血管疾病专家共识组.睡眠呼吸暂停与心血管专家共识.中华内科杂志,2009,48(12)：1059-1067.
[6]Mancia G,Grassi G.Mechanisms and clinical implications of blood pressure variability[J]. J Cardiovasc Pharmacol,2000,35(Suppl 4):15-19.
[7]Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure andheartratevariabilities:theohasamastudy[J]. Hypertension,2000,36(5):901-90 6.
[8]Celerma jer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan
ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet.1992 Nov 7; 340 (8828):1111-1115.
[9]Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease:an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing.J Am Coll Cardiol.2008,52 (8):686-717.
[10]Suzanne Oparil,Michael A. Weber. (吴寿岭译). Hypertension.北京大学医学出 版社,2008,789-790.
[11]苏定冯.自发性高血压大鼠用各种降压药治疗时血压变异性、压力感受器反射敏感性与靶器官损害.中华高血压杂志,2007,15(1)：38.
[12]Dazai Y, Iwata T, Hiwada K. Augmentation of baroreceptor reflex function by oral calcium supplementation in essential hypertension[J]. ClinExp Pharmacol Physiol,1994,21 (3):173-178.
[13]Siche JP, Singere P,De Gandemaris R, et al. Variability in arterial blood pressure at rest depends in the sensitivity of the baroreflex[J]. J Hypertens,1993,11[Suppl 5]:s176-sl77.
[14]Schiffrin EL. Vascular endothelia in hypertension [J]. Vascul Pharmacol, 2005,43 (1):19-29.
[15]Atkeson A, Yeh SY, Malhotra A, et al. Endothelial function in obstructive sleep apnea. Prog Cardiocascdis,2009,51:351-362.
[16]Cor ret ti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial2dependent flow2mediated vasodilation of the brachial artery:a report of the International Brachial Artery Reactivity Task Force [J]. J Am Coll Cardiol,2002,39 (2):257-265.
[17]Rossi R, Chiurlia E, Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women [J]. J Am Coll Cardiol,2004,44 (8):1636-1640.
[18]Rossi R, Chiurlia E, Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women [J]. J Am Coll Cardiol,2004,44 (8):1636-1640.
[19]Schiffrin EL. Vascular endothelia in hypertension [J]. Vascul Pharmacol, 2005,43 (1):19-29.
[20]陈明,胡申江,张健,等.不同危险度的高血压人血管内皮功能.高血压杂志,2006,14(4)：257-260.
[21]Xu JZ, Zhang Y, Wu SN, et al. Impaired endothelial function in hypertensive patients with target organ damage. J Hum Hypertens,2009, Mar5.
[22]季丽,刘运秋,徐应军.OSAHS合并高血压患者血清ET-1、NO和CRP水平与血压增高的关系山东医药,2010,8：96-98.
[23]王晓源,张林潮.阻塞性睡眠呼吸暂停低通气综合征与高血压.医学综述,2010,20：124-126.
[24]施熠炜,任寿安,杜永成.OSAHS合并高血压患者血内皮素、一氧化氮、肿瘤坏死因子-α和心钠素的临床研究.中西医结合心脑血管病杂志,2009,12：29-31.
[25]Gjφrup PH, Wessels J, Pedersen EB. Abnormally increased nitric oxide synthesis and increased endothelin-1 in plasma in patients with obstructive sleep apnoea. Scand J Clin Lab Invest,2008,68(5):375-385.
[26]陈瑀.内皮素与阻塞性睡眠呼吸暂停低通气综合征所致高血压的相关性探讨(附48 例分析).福建医药杂志,2010年,32(3)：22-23.
[27]夏宇,郗慧,米日古丽·司马,齐曼古力·吾守尔.阻塞性睡眠呼吸暂停低通气综合征患者血清血管内皮生长因子、一氧化氮的变化及意义.中华实用诊断与治疗杂志,2008,09：17-19.
[28]Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivates in obstructive sleep apnoea; response to CPAP therapy. Thorax,2000, 55:1046 1051.
[29]苏红,陈学远,张建全,李国秀,邓静敏.阻塞性睡眠呼吸暂停低通气综合征血管活性物质失衡的研究.广西医科大学学报,2004,21(3)：30-33
[30]Ryan S, Taylor CT,McNicholas WT. Systemic inflammation:a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Postgrad Med J,2009,85:693-698.
[31]GeorgoliosA, Batistatou A, Bonitsis N. et al. The role of inter-cellular adhesion molecule-1 in head and neck cancer [J]. ExpOncol,2006,28 (4): 270-274.
[32]Arnardottir; Miroslaw Mackiewicz; Thorarinn Gislason; Karen L. Teff; Allan I. Pack, MBChB. Molecular Signatures of Obstructive Sleep Apnea in Adults:A Review and Perspective. SLEEP,2009,32(4):447-470.
[33]K raiczi H, Caidahl K, Samuelsson A, et al. Impairment of vascular endothelial function and left ventricular filling:association with the severity of apnea-induced hypoxemia during sleep. Chest,2001,119 (4):1085.
[34]T akahashi S, Nakamura Y, Nishijima T, et al. Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome. Respir Med,2005,99(9):1125.
[35]Louisville ky. Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol,2000,119(2-3):189.
[36]A Barcelo, M. A Elorza,F. Barbe, et al. Angiotensin converting enzyme in patients with sleep apnoea syndrome:plasma activity and gene polymorphisms. Eur Respir,2001,17:728.
[37]Alastair J S Webb, Alastair JS Webb, Urs Fischer, Ziyah Mehta, Peter M Rothwell.Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke:a systematic review and meta-analysis.2010, the Lancet,375(9718),:906 915.
[38]Peter M Rothwell, Sally C Howard Eamon Dolan, Eoin O'Brien, Joanna E Dobson, Bjorn Dahlof, Neil R Poulter, Peter S Sever.Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Original Text The Lancet Neurology,2010.9, (5):469 480.
[39]T onelli M, Sacks F, Pfeffer M, et al. Effect of pravast at in on blood pressure in people with cardiovascular disease [J]. JH um Hypertens,2006,20 (8) 560-565.
[40]Borghi C, Dormi A, Veronesi M, et al. Associst ion between different lipid-lowering treatment strat egies and blood pressure cont rol in the Brisighella H eart Study[J]. Am H eart J,2004,148:285-292.
[41]Blanco-Colio LM, Osende JI, Mart in-Ventura JL, et al. St at ins in hypertension pat ients:Pot ent ial explanations for the ASCOT LLA study results [J].Drugs,2004,61:64-67.
[42]Peter M Rothwell, Sally C Howard, Eamon Dolan, Eoin O'Brien, Joanna E Dobson, Bjorn Dahlof, Neil R Poulter, Peter S Sever. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. The Lancet Neurology,2010,9(5), Pages 469 480.
[43]卢全生,雷燕,陈可冀。AT1R基因多态性与原发性高血压中医证型及降压中药疗效的关系中国中西医结合杂志2005,25(8)：682-685.
[44]缪化春,沈业寿. 有关天麻多糖的降压作用. 高血压杂志,2006,14(7)：531-533.[45]苏金平,刘干中,彭继道.五种中草药对钙通道阻滞作用的初步研究.中药药理与临床,2006,22(6)：45-46.
[46]Vanninen E,Tuunainen M,Kansanen M,ET-1 al. Cardiac sympatho-vagal balance during sleep apnea episodes. Clin Physiol,1996,16 (3):209.
[47]张毓,钟晓明.中药颗粒剂成型工艺的研究进展.海峡药学2010,22(1)27：28.
[48]何龙,姚尧.中药颗粒剂的研究现状及应用前景分析.中医中药,2010,17(9)：82-83。
[2]王文,王增武,陈伟伟.我国高血压防治的关键在基层.中华高血压杂志,2010,18(6)：501-503.
[3]Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S:The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med,1993, 328:1230-1235.
[4]Lavie P, Ben Yousef R,Rubin AE. Prevalence of sleep apnea syndrome among patients with essential hypertension. Am Heart J,1984,108:373-376.
[5]Peppard PE, Young T, Palta M & Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. NEngl J Med,2000,342, 1378 1384.
[6]Mohsenin V, Yaggi HK, Shah N, Dziura J. The effect of gender on the prevalence of hypertension in obstructive sleep apnea. Sleep Med,2009,10(7):759-762.
[7]Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease:an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing.J Am Coll Cardiol.2008,52 (8):686-717.
[8]Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension,2003,42:1206-1252.
[9]张京春,陈可冀.关于美国JNC-7高血压指南的评述.中国中西医结合杂志,2003,23(10)：724-726.
[10]Gonz a lez Bosc LV, Resta T, Walker B, Kanagy NL. Mechanisms of intermittent hypoxia-induced hypertension. J Cell Mol Med,2009, Oct 10.
[11]Atkeson A, Yeh SY, Malhotra A, Jelic S. Endothelial function in obstructive sleep apnea. Prog Cardiovasc Dis,2009,51 (5):351-362.
[12]Das AM, Khayat R. Hypertension in obstructive sleep apnea:risk and therapy. Expert Rev Cardiovasc Ther,2009,7 (6):619-626.
[13]Butt M, Dwivedi G, Khair O, Lip GY. Obstructive sleep apnea and cardiovascular disease. Int J Cardiol,2009, Jun 6.
[14]Gjφrup PH, Hedner J. Hypertension and obstructive sleep apnoea. Ugeskr Laeger, 2009,171 (25):2091-2094.
[15]Devulapally K, Pongonis R Jr, Khayat R. OSA:the new cardiovascular disease: part Ⅱ:Overview of cardiovascular diseases associated with obstructive sleep apnea.Heart Fail Rev,2009,14 (3):155-164.
[16]Dopp JM, Reichmuth KJ, Morgan BJ. Obstructive sleep apnea and hypertension: mechanisms, evaluation, and management. Curr Hypertens Rep,2007,9 (6):529-34.
[17]Hoffmann M, Bybee K, Accurso V, Somers VK. Sleep apnea and hypertension. Minerva Med,2004,95 (4):281-290.
[18]Weiss JW, Liu MD, Huang J. Physiological basis for a causal relationship of obstructive sleep apnoea to hypertension. Exp Physiol,2007,92 (1):21-26.
[19]Cooper VL, Elliott MW, Pearson SB, Taylor CM, Mohammed MM, Hainsworth R. Daytime variability of baroreflex function in patients with obstructive sleep apnoea:implications for hypertension. Exp Physiol,2007,92 (2):391-398.
[20]Ziegler M G, Mills PJ, Loredo JS, et al. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest,2000,120:887-893.
[21]Vanninen E,Tuunainen M,Kansanen M, et al. Cardiac sympatho2 vagal balance during sleep apnea episodes. Clin Physiol,1996,16 (3):209.
[22]Coy TV, Dimsdale J E, Ancol i-Israel S, et al. Sleep apnea and sympathelic nervous system activety. J Sleep Res,1996,5 (1):42.
[23]罗荧荃,黄国庆,杨宇.慢性间歇低氧诱发大鼠高血压模型的建立.中国新药杂志,2006 15(22)：1930-1933.
[24]袁志明,陈宝元,王佩显,蒋汉涛,张敬霞.慢性间歇低氧诱发大鼠高血压发病过程中一氧化氮和一氧化氮合酶的变化.J Clin Cardiol (China),2005,21(8):472-475.
[25]Gonz a lez-Martin MC, Vega-Agapito V, Prieto-Lloret J, Agapito MT, Castaneda J, Gonzalez CAdv Exp Med Biol. Effects of intermittent hypoxia on blood gases plasma catecholamine and blood pressure,2009,648:319-328.
[26]Gard:-Rio F, Racionero MA, Pino JM, et al. Sleep and hypertension. Chest, 2000,117(5):1414-1425.
[27]Yoon IY, Jeong DU. Degree of arousal is most correlated with blood pressure reactivity during sleep in obstructive sleep apnea. J Korean Med Sci 2001,16:707-711.
[28]钟旭,肖毅.降压药对于阻塞性睡眠呼吸暂停低通气综合征患者相关动脉血管反应的作用.中华结核和呼吸杂志,2005,28(6)：377-381.
[41]杜以明,薛玉文.OSAHS合并高血压与血浆内皮素关系的研究.新医学,2007,38(3)：171-173.
[42]王廷础,卢红霞,王欣,王岩,张丙峰.阻塞性睡眠呼吸暂停低通气综合征合并高血压患者睡眠结构分析及血清内皮素-1的测定.中华耳鼻咽喉科杂志,2004,39(2)：55-58.
[43]陈瑀.内皮素与阻塞性睡眠呼吸暂停低通气综合征所致高血压的相关性探讨(附48例分析).福建医药杂志,2010年,32(3)：22-23.
[44]陈光辉,王士雯,张文莉,王莉,盖鲁粤.血管活性物质在睡眠呼吸暂停综合征合并高血压中作用的研究.解放军医学杂志,2006,31(2)：147-149.
[45]王国付,钦光跃,吴健,吴金彦,顾亮.阻塞性睡眠呼吸暂停低通气综合征血管内皮细胞功能的研究中国实用内科杂志,2006,26(21)：1709-1711.
[46]马秀芬,平芬,刘美霞,凌亦凌.血栓素A2、前列环素与阻塞性睡眠呼吸暂停低通气综合征及其合并高血压的相关性研究.《临床荟萃》,2005,20(24)：1396-1399.
[47]Baylor P,Mouton A, Shamoon HH, et al. Increased norepinephrinevariability in patients with sleep apnea syndrome. AmJ Med,1995,99 (6):611.
[48]Gibbons GH, Deanfield J, Donald A, Ferri C1, et. Endothelial function as a determinant of vascular function and structure:a new therapeutic target. Am J Cardiol 1997,79:3 873.
[49]Moller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens,2003,274 280.
[50]陈光辉,王士雯,张文莉,王莉,易军.睡眠呼吸暂停综合征对部分心血管活性物质变化的影响.军医进修学院学报,2005,26(2)：137.
[51]Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivates in obstructive sleep apnoea; response to CPAP therapy. Thorax,2000, 55:1046 1051.
[52]杨朝,张锦.阻塞性睡眠呼吸暂停低通气综合征患者血浆ET-1、NO水平的变化及nCPAP对其影响.中国老年学杂志,2004,24(9)：793-795,
[53]苏红,陈学远,张建全,李国秀,邓静敏.阻塞性睡眠呼吸暂停低通气综合征血管活性物质失衡的研究.广西医科大学学报,2004,21(3)：30-33.
[54]BOULANGER C M. Secondary endothelial dysfunction:hypertension and heart-failure [J]. J Mol Cell Cardiol,1999,31:39-49.
[55]DEAM R T, WILCOX I. Possible at herogenic effect s of hypoxia during obstructive sleep apnea [J]. Sleep,1993,16 (8):15-21.
[56]薛静,汪贺媛,孙磊,李立新,高仲群,黄舒.OSAHS合并高血压患者内皮素和降钙素基因相关肽检测.中国耳鼻咽喉头颈外科,2005,12(6)：47-49.
[57]Phillips CL, Yang Q, Williams A, Roth M, Yee BJ, Hedner JA, Berend N, Grunstein RR. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnoea. J Sleep Res,2007,16 (2):217-225.
[58]窦晓辉,曾亮,汪志伟.阻塞性睡眠呼吸暂停低通气综合征患者炎症因子水平变化.中国耳鼻咽喉头颈外科,2007,14(5)：76-78.
[59]牛红丽,马利军,王海播,况红艳.OSAHS合并高血压患者血清炎症因子浓度与血压的关系.中国实用医药,2008,30期
[60]张黎军,刘淑华,刘昌慧,刘涓.阻塞性睡眠呼吸暂停低通气综合征患者细胞粘附分子水平的研究.微循环学杂志,2005,04期
[61]康健,王赞峰.炎症、氧化应激与阻塞性睡眠呼吸暂停低通气综合征.中华结核和呼吸杂志,2006,29(4)：226-227.
[62]龙利民,杨宇,黄国庆.固性高血压合并OSAHS患者nCPAP治疗前后血压与血清高敏C反应蛋白水平的研究.中国医师杂志,2006,8(10)：1352-1354.
[63]刘志.老年高血压病发阻塞性睡眠呼吸暂停综合征患者血压特点及与炎症因子的关系.心脏杂志,2008,20(5)：574-587.
[64]Riha RL, Brander P, Vennelle M, et al. Tumour necrosis factor2a (2308) gene polymorphism in obstructive sleep apnoea2hypopnoea syndrome [J]. Eur Respir J,2005,26(4):673-678.
[65]魏建军,张希龙,李翀.阻塞性睡眠呼吸暂停低通气综合征患者炎症因子与高血压的相关性.内科理论与实践,2009,4(5)：404-407.
[66]张敏艳.阻塞性睡眠呼吸暂停低通气综合征与白细胞介素-6关系的临床研究.山西医药杂志,2008,37(2)：164-165.
[67]李艳,温雪萍,陈学奎,颜志军,王忠慧.阻塞性睡眠呼吸暂停综合征免疫网络及其与临床的相关性.中国医师进修杂志,2006,29(8)：19-20.
[68]李延忠,张万荣,王廷础,卢红霞,王岩,王欣.粘附分子在阻塞性睡眠呼吸暂停低通气综合征合并高血压发病中的作用.中华结核和呼吸杂志,2007,27(8)：511-514.
[69]Schulz R, Hummel C, Heinemam S, et al. Serum levels of vascular endothelial growth factor and elevated in patients with obstructive sleep apnea and severe night time hypoxia[J]. Am J Respir Crit Care Med,2002,165(1):67-70.
[70]Teramoto S, Kume H, Yamamoto H, et al. Effects of oxygen administration on the circulating vascular endothelial growth factor (VEGF) levelsin patients with obstructive sleep apne syndrome [J]. Intern Med,2003,42(8):681-685.
[71]Takekoshi K, Ishii K, Nanmoku T, Shibuya S, Kawakami Y, Isobe K, Nakai T. Leptin stimulates catecholamine synthesis in a PKC-dependent manner in cultured porcine adrenal medullary chromaffin cells. Endocrinology,2001,142 (11):4861-4871.
[72]吕昌惠,郭宜,崔淑芬.阻塞性睡眠呼吸暂停低通气综合征患者血清瘦素水平的研究.中国综合临床,2006,22(9)：780-783.
[73]张健,叶珏,裴卫东,格桑罗布,惠汝太,刘力生.不同程度阻塞性睡眠呼吸暂停合并高血压与血管紧张素转换酶基因多态性的比较研究.血压杂志,2000,8(2)：129-131.
[74]Koyama RG, Drager LF, Lorenzi-Filho G, Cintra FD, Pereira AC, Poyares D, Krieger JE, Castro RM, Tufik S, de MelloMT, Pedrazzoli M. Reciprocal interactions of obstructive sleep apnea and hypertension associated with ACE I/D polymorphism in males. Sleep Med,2009,22.
[75]Bostrom KB, Hedner J, Melander 0, Grote L, Gullberg B, Rastam L, Groop L, Lindblad U. Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension. J Hypertens,2007,25 (4):779-783.
[76]李延忠,张万荣,王廷础,卢红霞,王欣,王岩.OSAHS并发高血压患者血管紧张素转换酶基因多态性及血清血管紧张素Ⅱ水平测定.J Clin Otorhinolaryngol, 2004,18(8)：11-14.
[77]黄蓉,黄席珍,黎明,肖毅,张健.瘦素受体基因G1n223Arg多态性与阻塞性睡眠呼吸暂停低通气综合征的关系.中华结核和呼吸杂志,2003,26(9)：517-519.
[78]王胜国,周本忠,孙敬武,胡勇,李皓,兰兰.阻塞性睡眠呼吸暂停低通气综合征患者咽部组织中瘦素受体表达的初步研究.中华耳鼻咽喉头颈外科杂志,2005,40(10)：787-788.
[79]岳伟华,刘破资,郝伟,张向晖,王小平,张纪水,周旭辉,谢永标,倪明.睡眠呼吸暂停综合征与5-羟色胺转运体基因多态性的关联分析.中华医学遗传学杂志,2005,22(5)：533-535.
[80]阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案).中华医学会呼吸病学分会睡眠呼吸疾病学组,2001年.
[81]孙书臣,刘艳骄.多导睡眠仪实用技术手册.人民军医出版社.
[82]Lavie-Nevo K, Pillar G. Evening-morning differences in blood pressure in sleep apnea syndrome:effect of gender. A m J Hyper tens,2006,19 (10):1064-9.
[83]童茂荣.多导睡眠图学技术与理论.人民军医出版社,7.
[84]Chan AS, Phillips CL, Cistulli PA. Obstructive sleep apnoea-an update. Intern Med J,2009,7.
[85]Zou D, Grote L, Peker Y, Lindblad U, Hedner J. Validation a portable monitoring device for sleep apnea diagnosis in a population based cohort using synchronized home polysomnography. Sleep,2006,29 (3):367-374.
[86]林其昌,陈公平,丁海波,邓朝胜,王春娥.持续气道正压通气治疗老年人阻塞性睡眠呼吸暂停低通气综合征合并高血压的疗效.中华老年医学杂志,2005,24(8)：595-597.
[87]赵军,郝芙蓉,汪贺媛,魏小刚.经鼻持续气道正压通气治疗睡眠呼吸暂停综合征合并高血压的临床研究.《临床荟萃》,2008,23(15)：1084-1085.
[88]徐江祥,刘志强,黄小红,胡星兰,王霞,夏斌,曹玲玲,蔡平,汤杰,徐保朝,余达训.气道正压通气治疗高血压伴阻塞性睡眠呼吸暂停低通气综合征.中华高血压杂志,2007,15(1)：49-52.
[89]李莉,吴海英,刘力生.睡眠呼吸暂停综合征与高血压治疗.中华心血管病杂志,2004,32(1)：30-32.
[90]秦淑辉,封彦凤,吕志平,肖文良.阻塞性睡眠呼吸暂停低通气综合征合并高血压的治疗.《临床荟萃》,2009,24(8)：697-699.
[91]黎燕群,张希龙.持续气道正压通气治疗对阻塞性睡眠呼吸暂停综合征患者难治性高血压的影响.南京医科大学学报(自然科学版),2008,28(2)：210-214.
[92]Norman D, Loredo JS, Nelesen RA, Ancoli-Israel S, Mills PJ, Ziegler MG, Dimsdale JE. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. H ypertension, 2006,47 (5):840-845.
[93]Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension,2007,50 (2):417-423.
[94]Middleton S, Vermeulen W, Byth K, Sullivan CE, Middleton PG.Treatment of obstructive sleep apnoea in Samoa progressively reduces daytime blood pressure over 6 months. Respirology,2009,14 (3):404-410.
[95]Lattimore JL, Wilcox I, Skilton M, Langenfeld M, Celermajer DS. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax,2006,61 (6):491-495.
[96]Tun Y, Hida W, Okabe S, Ogawa H, Kikuchi Y, Oikawa M, Kitamuro T, Kunio S. Can nasal continuous positive airway pressure decrease clinic blood pressure in patients with obstructive sleep apnea? Tohoku J Exp Med,2003,201 (3):181-190.
[97]Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients.Eur Respir J,2006,27 (6):1229-1235.
[98]Hermida RC, Zamarron C, Ayala DE, Calvo C. Effect of continuous positive airway pressure on ambulatory blood pressure in patients with obstructive sleep apnoea. Blood Press Monit,2004,9 (4):193-202.
[99]Kim JH, Kwon MS, Song HM, Lee BJ, Jang YJ, Chung YS. Compliance with positive airway pressure treatment for obstructive sleep apnea. Clin Exp Otorhinolaryngol, 2009,2 (2):90-96.
[100]弓艳辉,明彦,杨伟国.高血压患者合并阻塞性睡眠呼吸暂停低通气综合征正压通气与外科治疗对血压的影响.中国老年学杂志,2008,28(4)：811-812.
[101]Andr e n A, Sjoquist M, Tegelberg A. Effects on blood pressure after treatment of obstructive sleep apnoea with a mandibular advancement appliance-a three-year follow-up. J Oral Rehabil,2009,36(10):719-725.
[102]李惠兰,李瑛,王蓓,闫学军,刘瑛年,宋满景.口腔矫治器治疗阻塞性睡眠呼吸暂停综合征型高血压老年患者疗效观察.中华结核和呼吸杂志,2001,24(3)：180.
[103]霍艳明,李丹,王薇,丁烈,李明贤,马英明,王辉奇,于洁,孙伟.高血压病合并睡眠呼吸暂停低通气综合征的临床研究.中国医药指南,2010,8(30)：14-15.
[104]王蕾.高血压合并阻塞性睡眠呼吸暂停低通气综合征中医证候的临床研究.2010年,南京中医药大学硕士学位论文.
[105]田华,李晓兵,霍素婷.断调波治疗睡眠呼吸暂停综合征合并高血压病的临床研究. 河北中医,2007,29(5)：397-436.
[1061粟俊,李磊,钟力平.黄连温胆汤治疗睡眠低通气的临床研究.中医药临床杂志,2004,16(5)：423-424.
[107]郭湘芳,粟俊,吕晶.通塞消栓汤治疗脑梗死兼阻塞性睡眠呼吸暂停低通气综合征30例.中国中医药信息杂志,2007,14(6)：13-14.
[108]粟俊,李磊,钟力平,邓映辉.升陷汤联合都可喜治疗阻塞性睡眠呼吸暂停低通气综合征38例临床观察.中医杂志,2010,(7)：600-602.
[109]关风岭,关思友.自拟桔梗愈鼾汤治疗睡眠呼吸暂停综合征20例临床研究.四川中医,2005,23(12)：49-50.
[110]杨水清,朱斯洪.自拟化痰理气汤治疗阻塞性睡眠呼吸暂停低通气综合征疗效观察.中医药临床杂志,2006,18(2)：146-147.
[111]胡良冈,徐晓梅,王良兴,龚永生,范小芳,王胜初.经皮电刺激治疗阻塞性睡眠呼吸暂停综合征的研究.中国生物医学工程学报,2005,24(3)：370-373.
[112]王晓红,肖兰英,王保法,袁雅冬,潘文森,石玉珍.耳穴贴压疗法对阻塞性睡眠呼吸暂停综合征患者睡眠结构的影响.中医杂志,2006,47(8)：584-586.
[113]陈敏,江学勤,陈利华.针刺治疗阻塞性睡眠呼吸暂停综合征的临床研究.四川中医.2005,23(10)：104-105.
[114]Hedner J, Grote L, Zou D. Pharmacological treatment of sleep apnea:current situation and future strategies.Sleep Med Rev.2008,12(1):33-47.
[115]Pack AI, Gislason T. Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis,2009,51 (5):434-451.
[116]Bradley TD, Floras JS, Obstructive sleep apnoea and its cardiovascular consequences. Lancet,2009,373(9657):82-93.
[117]张健,谢晋湘,惠汝太,柳志红,刘力生.阿罗洛尔降压疗效和对睡眠呼吸障碍的影响.中国循环杂志,1998,13(6)：331-333.
[118]陈明,孙雷.伴有阻塞性睡眠呼吸暂停综合征高血压患者的夜间药物降压对策.江苏医药,2006,32(9)：862-863.
[119]平芬,李贤,苏力,高凤岐,赵景春,韩书芝,田蓉.海捷亚对阻塞性睡眠呼吸暂停低通气综合征合并高血压患者降压疗效和睡眠呼吸的影响.中国老年学杂志,2005,25(9)：1030-1032.
[120]张健,谢晋湘,惠汝太,许玉春,龚维如,汪芳,李莉,李天德,邓开伯,刘力生.赖诺普利治疗原发性高血压及其合并睡眠呼吸暂停的临床试验.高血压杂志,1998,6(4)：257-259.
[121]李莉,谢晋湘,李喜梅,张彬,丁昌玲,刘力生.抑平舒的降压效果和对睡眠呼吸障碍的影响.高血压杂志,1999,7(4)：343-346.
[122]HOLGER KRAICZI, JAN HEDNER, YUKSEL PEKER, and LUDGER GROTE. Comparison of Atenolol, Amlodipine, Enalapril,Hydrochlorothiazide, and Losartan for Antihypertensive Treatment in Patients with Obstructive Sleep Apnea. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,2000:1423-1428.
[123]Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D.Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol,2009,53 (15):1309-1317.
[124]Okcay A, Somers VK, Caples SM. Obstructive sleep apnea and hypertension. J Clin Hyper tens (Greenwich),2008,10(7):549-555.
[1]陈懿宇,张京春.高血压血管内皮机制的中西医研究现状.中国老年学杂志,2010,20(30)：3010-3013.
[2]Gkaliagkousi E, Douma S, Zamboulis C, Ferro A. Nitric oxide dysfunction in vascular endothelium and platelets:role in essential hypertension. J Hypertens, 2009,27(12):2310-20.
[3]Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C. Essential hypertension:is there a role for inflammatory mechanisms? Cardiol Rev,2009,17 (5):216-21.
[4]陈明,胡申江,张健,等.不同危险度的高血压人血管内皮功能.高血压杂志,2006,14(4)：257-260.
[5]de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens, 2010,24(6):373-9.
[6]李卫萍,孙明,周宏研,等.原发性高血压患者血管内皮功能失调与活性氧的关系及阿托他汀治疗的影响[J].中国现代医学杂志,2005,15(7)：1096-1103.
[7]李小兵,冼绍祥,洪永敦.高血压病证候与内皮功能失调及自由基损伤的关系探讨.中国中医基础医学杂志,2005,11(5)：62-364.
[8]Rossi R, Chiurlia E,Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women [J]. J Am Coll Cardiol,2004,44 (8):1636-1640.
[9]Suwaidi J, Hamasaki S, H igano S, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation,2000, 101:948-954.
[10]Gokce N, Keaney JF J r, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function:a prospective study. Circulation,2002,105:1567-1572.
[11]Shimizu Y, Nagaya N,Teranishi Y,et al.Ghrenlin improves endothelial dysfunction through growth hormone independent mechanisms in rats [J].Biochem Biophys Res Comm un,2003,310 (3):830.
[12]Li GZ,Jing W,Zhao J, et al.Ghrelin blunted vascular calcification in vivo and in vitro in rats[J]. Regul Pept,2005,129 (1):167.
[13]Nakamura T, Mizuno S,Matsumoto K, et al. Myocardial protection from ischemia Preperfusion injury by endogenous and exogenous HGF. J Clin Invest,2000,106 (12):1511-1519.
[14]Makin AJ,Blann AD, Chung NA, et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor [J]. Eur Heart J,2004,25 (5):371-376.
[15]Jimenez JJ, Jy W,Mauro L, et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura (TTP):findings from brain and renal microvascular cell culture and patients with active disease [J].Br J Haematol,2001,112:81-90.
[16]王妍,陶军,涂昌,陈龙,杨震,徐明国,王洁梅,黄奕俊.高血压患者循环内皮细胞微颗粒水平的变化.中华老年心脑血管病杂志,2006,8(4)：222-224.
[17]de la Pena M, Barcel o A, Barbe F, et al. Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration,2008,76(1):28-32.
[18]周丽娜,余毅,吴可贵.心血管疾病氧化应激对内皮祖细胞的影响.中华高血压杂志2007,15(11)：893-895.
[19]Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery:a report of the International Brachial Artery Reactivity Task Force [J]. J Am Coll Cardiol,2002,39(2):257-265.
[20]孙妍,王国干,沈磊,等.高血压患者血管内皮功能及颈动脉内-中膜厚度与冠心病事件关系的研究.中国超声医学杂志,2007,23(12)：908-910.
[21]Tio RA,Monnink SH,Amoroso G, et al. Safety evaluation of routine intracoronary acetylcholine infusion in patients undergoing a first diagnostic coronary angiogram [J]. J Investig Med,2002,50 (2):133-139.
[22]Kjaer A,Meyer C, Nielsen FS, et al. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction:a PET study of myocardial perfusion in diabetes [J].J Nucl Med,2003,44 (1):19-23.
[23]Modena M, Bonetti L, Coooi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. Jam Coll Cardiol,2002,40: 505-5101.
[24]黄震华.抗高血压药物与血管内皮功能.中国新药与临床杂志,2005,5(24)：398-401.
[25]TADDEI S, V IRD IS A, GH IADON IL, et al. Effects of antihypertensive drugs on endothelial dysfunction:clinical implications [J]. Drugs,2002,62 (2) 265-284.
[26]宋月霞,王希柱,钟雪莲.非洛地平对高血压患者血浆生长素水平和血管内皮功能的影响.中国药房,2007,18(20)：1572-1573.
[27]MU IESAN ML, SALVETTIM, MONTEDURO C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension [J]. Hypertension,1999,33(2):575-580.
[28]吕纳强,何苒,宋卫华,党爱民.伊贝沙坦对原发性高血压患者血浆内皮素及循环内皮细胞的影响.中华高血压杂志,2007,15(6)：465-467.
[29]Tzemos N,Lim PO,MacDonald TM.Valsartan improves endothelial dysfunction in hypertension:a randomized,double-blind study[J]. Cardiovasc Ther,2009, 27(3):151-8.
[30]Galiavich AS, Khamidullina AR, Galiavich RA. Effect of antihypertensive drugs on some humoral parameters of endothelial function[J]. Kardiologiia,2009,49 (5): 30-3.
[31]刘妙,萧佩玉.苯那普利对原发性高血压患者内皮功能和血清细胞因子水平的影响.中山大学学报,2007,28(6)：215-217.
[32]Sozen AB, Kayacan MS, Tansel T, Celebi A, Kudat H, Akkaya V, Erk 0, Hatipoglu I, Demirel S. Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. J Int Med Res.2009,37(4):996-1002.
[33]Musikhina NA, Iuferova OV, Gapon LI, Makhneva EA, Belikova EA, Petelina TI, Todosi□chuk VV. Structural-functional properties of the vascular wall in hypertensive patients with coronary heart disease:effects of felodipin and perindopril. Ter Arkh.2009,81 (9):13-6.
[34]Family Practice News,2007-04-12.顽固性高血压治疗新药-内皮素受体拮抗剂.中华高血压杂志,2007,15(5),436.
[35]张臣,邢之华,刘卫平,冯雪辉,蔡昌龙,谭海彦.高血压病中医证型与血浆内皮素及血压的相关性研究.辽宁中医杂志2005,32(1)：6-7.
[36]谭海彦,朱莉,邢之华,刘卫平,蔡昌龙,张臣.天麻钩藤饮改善高血压患者内皮功能的机理研究.山东医药,2005,45(1)：12-13.
[37]王书梅,刘建.天麻钩藤饮对66例高血压患者一氧化氮和内皮素影响的临床研究.现代预防医学,2006,33(6)：1052-1053.
[38]林展增,邢之华,蔡昌龙,谭海彦,张臣.天麻钩藤饮对肝阳上亢型原发性高血压患者血浆内皮素的影响.中国临床康复,2004,8(27)：5992-5993.
[39]张焱,陈咸川,何立人,童仙君,黄薇.化湿利水泄浊合剂对高血压病患者血管内皮依赖性舒张功能的影响.上海中医药杂志,2005,39(6)：14-16.
[40]杜立峰,杨杰,孙师元,王小闯,吴喜利.平肝降压胶囊对原发性高血压患者血浆内皮素和血管紧张素Ⅱ的影响.中国临床康复,8(36)：8250-8251.
[41]卢全生.清眩胶囊治疗轻中度高血压病的实验和临床研究.中国中医研究院博士学位论文,2003.
[42]谢元华,张京春,蒋跃绒,等.陈可冀辨治高血压病医案的数据挖掘分析.中西医结合心脑血管病杂志,2008,6(2)：135-136.
[43]刘婷,张毅,秦彩玲,孙玉茹.桂枝汤降压作用机制初探——对血浆及组织中ET、NT含量的影响。中国药学杂志,2005,3(40)：421-423.
[44]徐树楠,张再康,冯瑞雪,刘海丽,张凯.活血降压方对自发性高血压大鼠血压及血浆ET、血清NO含量的影响.中药药理与临床,2004,20(5)：39-40.
[45]徐树楠,侯仙明,王文智,贾云芳.潜阳通络方对肝阳上亢型高血压病大鼠血压和ET、ANP的影响.中国中医基础医学杂志,2007,13(12)：908-909.
[46]李景新,王贞,王蓉,刘克敬,陈连璧.沙苑子总黄酮对自发性高血压大鼠血脂及内皮素活性的影响.中国微循环,2004,8(5)：336-337.
[47]金龙,周文泉.络活胶囊治疗高血压病的实验研究.中国中西医结合杂志,2004,24：18-20.
[48]陈双厚,刘瑞华,李世洁.降压舒心胶囊对实验肾性高血压大鼠血清内皮素、血浆血管紧张素Ⅰ、Ⅱ含量的影响.中药药理与临床,2004,20(3)：28-29.
[49]赵萍,陈洁,洪永敦,曾燕静.温胆泄浊法对痰浊型高血压病患者血管内皮舒张功能与粥样硬化改善作用的超声研究.中国中西医结合杂志,2007,27(1)：21-24.
[50]王晓君,黄文增,张步延.联服川芎素、培哚普利与单服培哚普利对高血压患者血管内皮功能和血压的影响.中华高血压杂志,2006,14(12)：993-996.
[51]李浩,郭明冬,刘剑刚.降压胶囊联合尼莫地平对自发性高血压大鼠ET、CGRP及AngⅡ水平的影响.中国老年学杂志,2007,27：2178-2180.
[1]Fletcher, E. C., R. D. DeBehnke, M. S. Lovoi, and A. B. Gorin. Undiagnosed sleep apnea in patients with essential hypertension.Ann. Intern. Med.1985,103:190-195.
[2]Olson, L. G., M. T. King, M. J. Hensley, and N. A. Saunders. A community study of snoring and sleep-disordered breathing:health outcomes. Am. J. Respir. Crit. Care Med. 1995,152:717-720.
[3]Rauscher, H., D. Formanek, W. Popp, and H. Zwick. Nasal CPAP and weight loss in hypertensive patients with obstructive sleep apnoea. Thorax.1993,48:529-533.
[4]McArdle, N., G. Devereux, H. Heidarnejad, H. M. Engleman, T. W. Mackay, and N. J. Douglas. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am. J. Respir. Crit. Care Med.1999,159:1108-1114.
[5]I. Kantola, E.Rauhala, M. Erkinjuntti, L Mansury. Sleep disturbances in hypertension:A double-blind study between isradipine and metoprolol. Journal of Cardiovascular Pharmacology.1991,18(1):41-45.
[6]J Heitmann, L Grote, L. Knaack. U Kohler. M. Hinder, JH Peter.. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea. Eur J Clin Pharmacol. 1998,54:691-696.
[7]Bartel P.R, Loock M, Becker P. Short-term antihypertensive medication does not exacerbate sleep-disordered breathing in newly diagnosed hypertensive patients. American Journal of Hypertension.1997,10(6):640-645.
[1]阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案).中华医学会呼吸病学分会睡眠呼吸疾病学组,2001年。
[2]. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5 (2):136-143.
[3]McArdle, N., G. Devereux, H. Heidarnejad, H. M. Engleman, T. W. Mackay, and N. J. Douglas. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am. J. Respir. Crit. Care Med.1999,159:1108 1114.
[4]粟俊,李磊,钟力平.黄连温胆汤治疗睡眠低通气的临床研究.中医药临床杂志,2004,16(5)423-424.
[5]郭湘芳,粟俊,吕晶.通塞消栓汤治疗脑梗死兼阻塞性睡眠呼吸暂停低通气综合征30例.中国中医药信息杂志,2007,14(6)13-14.
[6]粟俊,李磊,钟力平,邓映辉.升陷汤联合都可喜治疗阻塞性睡眠呼吸暂停低通气综合征38例临床观察.中医杂志,2010,(7)600-602.
[7]关风岭,关思友.自拟桔梗愈鼾汤治疗睡眠呼吸暂停综合征20例临床研究.四川中医,2005,23(12)49-50.
[8]杨水清,朱斯洪.自拟化痰理气汤治疗阻塞性睡眠呼吸暂停低通气综合征疗效观察.中医药临床杂志,2006,18(2)146-147.
[9]广东省卫生厅编印.广东省常见病基本诊疗规范.第一册,内部材料,1998,39-41
[1]Whitworth JA,World Health Organization, International Society of Hypertension Writing Group.2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension(Guidelines and recommendations). J Hypertens,2003,21:1983-1992.
[2]中华人民共和国卫生部.中国高血压防治指南(2005年修订版).2005.
[3]郑筱萸.中药新药临床研究指导原则.北京：中国医药科技出版社,2002：73-77.
[4]中华医学会呼吸病学分会睡眠呼吸疾病学组.阻塞性睡眠呼吸暂停低通气综合征诊治指南(草案)[J].中华结核和呼吸杂志,2002,25(3)：195-198.
[5]睡眠呼吸暂停与心血管疾病专家共识组.睡眠呼吸暂停与心血管专家共识.中华内科杂志,2009,48(12)：1059-1067.
[6]Mancia G,Grassi G.Mechanisms and clinical implications of blood pressure variability[J]. J Cardiovasc Pharmacol,2000,35(Suppl 4):15-19.
[7]Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure andheartratevariabilities:theohasamastudy[J]. Hypertension,2000,36(5):901-90 6.
[8]Celerma jer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan
ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet.1992 Nov 7; 340 (8828):1111-1115.
[9]Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease:an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing.J Am Coll Cardiol.2008,52 (8):686-717.
[10]Suzanne Oparil,Michael A. Weber. (吴寿岭译). Hypertension.北京大学医学出 版社,2008,789-790.
[11]苏定冯.自发性高血压大鼠用各种降压药治疗时血压变异性、压力感受器反射敏感性与靶器官损害.中华高血压杂志,2007,15(1)：38.
[12]Dazai Y, Iwata T, Hiwada K. Augmentation of baroreceptor reflex function by oral calcium supplementation in essential hypertension[J]. ClinExp Pharmacol Physiol,1994,21 (3):173-178.
[13]Siche JP, Singere P,De Gandemaris R, et al. Variability in arterial blood pressure at rest depends in the sensitivity of the baroreflex[J]. J Hypertens,1993,11[Suppl 5]:s176-sl77.
[14]Schiffrin EL. Vascular endothelia in hypertension [J]. Vascul Pharmacol, 2005,43 (1):19-29.
[15]Atkeson A, Yeh SY, Malhotra A, et al. Endothelial function in obstructive sleep apnea. Prog Cardiocascdis,2009,51:351-362.
[16]Cor ret ti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial2dependent flow2mediated vasodilation of the brachial artery:a report of the International Brachial Artery Reactivity Task Force [J]. J Am Coll Cardiol,2002,39 (2):257-265.
[17]Rossi R, Chiurlia E, Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women [J]. J Am Coll Cardiol,2004,44 (8):1636-1640.
[18]Rossi R, Chiurlia E, Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women [J]. J Am Coll Cardiol,2004,44 (8):1636-1640.
[19]Schiffrin EL. Vascular endothelia in hypertension [J]. Vascul Pharmacol, 2005,43 (1):19-29.
[20]陈明,胡申江,张健,等.不同危险度的高血压人血管内皮功能.高血压杂志,2006,14(4)：257-260.
[21]Xu JZ, Zhang Y, Wu SN, et al. Impaired endothelial function in hypertensive patients with target organ damage. J Hum Hypertens,2009, Mar5.
[22]季丽,刘运秋,徐应军.OSAHS合并高血压患者血清ET-1、NO和CRP水平与血压增高的关系山东医药,2010,8：96-98.
[23]王晓源,张林潮.阻塞性睡眠呼吸暂停低通气综合征与高血压.医学综述,2010,20：124-126.
[24]施熠炜,任寿安,杜永成.OSAHS合并高血压患者血内皮素、一氧化氮、肿瘤坏死因子-α和心钠素的临床研究.中西医结合心脑血管病杂志,2009,12：29-31.
[25]Gjφrup PH, Wessels J, Pedersen EB. Abnormally increased nitric oxide synthesis and increased endothelin-1 in plasma in patients with obstructive sleep apnoea. Scand J Clin Lab Invest,2008,68(5):375-385.
[26]陈瑀.内皮素与阻塞性睡眠呼吸暂停低通气综合征所致高血压的相关性探讨(附48 例分析).福建医药杂志,2010年,32(3)：22-23.
[27]夏宇,郗慧,米日古丽·司马,齐曼古力·吾守尔.阻塞性睡眠呼吸暂停低通气综合征患者血清血管内皮生长因子、一氧化氮的变化及意义.中华实用诊断与治疗杂志,2008,09：17-19.
[28]Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivates in obstructive sleep apnoea; response to CPAP therapy. Thorax,2000, 55:1046 1051.
[29]苏红,陈学远,张建全,李国秀,邓静敏.阻塞性睡眠呼吸暂停低通气综合征血管活性物质失衡的研究.广西医科大学学报,2004,21(3)：30-33
[30]Ryan S, Taylor CT,McNicholas WT. Systemic inflammation:a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Postgrad Med J,2009,85:693-698.
[31]GeorgoliosA, Batistatou A, Bonitsis N. et al. The role of inter-cellular adhesion molecule-1 in head and neck cancer [J]. ExpOncol,2006,28 (4): 270-274.
[32]Arnardottir; Miroslaw Mackiewicz; Thorarinn Gislason; Karen L. Teff; Allan I. Pack, MBChB. Molecular Signatures of Obstructive Sleep Apnea in Adults:A Review and Perspective. SLEEP,2009,32(4):447-470.
[33]K raiczi H, Caidahl K, Samuelsson A, et al. Impairment of vascular endothelial function and left ventricular filling:association with the severity of apnea-induced hypoxemia during sleep. Chest,2001,119 (4):1085.
[34]T akahashi S, Nakamura Y, Nishijima T, et al. Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome. Respir Med,2005,99(9):1125.
[35]Louisville ky. Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol,2000,119(2-3):189.
[36]A Barcelo, M. A Elorza,F. Barbe, et al. Angiotensin converting enzyme in patients with sleep apnoea syndrome:plasma activity and gene polymorphisms. Eur Respir,2001,17:728.
[37]Alastair J S Webb, Alastair JS Webb, Urs Fischer, Ziyah Mehta, Peter M Rothwell.Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke:a systematic review and meta-analysis.2010, the Lancet,375(9718),:906 915.
[38]Peter M Rothwell, Sally C Howard Eamon Dolan, Eoin O'Brien, Joanna E Dobson, Bjorn Dahlof, Neil R Poulter, Peter S Sever.Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Original Text The Lancet Neurology,2010.9, (5):469 480.
[39]T onelli M, Sacks F, Pfeffer M, et al. Effect of pravast at in on blood pressure in people with cardiovascular disease [J]. JH um Hypertens,2006,20 (8) 560-565.
[40]Borghi C, Dormi A, Veronesi M, et al. Associst ion between different lipid-lowering treatment strat egies and blood pressure cont rol in the Brisighella H eart Study[J]. Am H eart J,2004,148:285-292.
[41]Blanco-Colio LM, Osende JI, Mart in-Ventura JL, et al. St at ins in hypertension pat ients:Pot ent ial explanations for the ASCOT LLA study results [J].Drugs,2004,61:64-67.
[42]Peter M Rothwell, Sally C Howard, Eamon Dolan, Eoin O'Brien, Joanna E Dobson, Bjorn Dahlof, Neil R Poulter, Peter S Sever. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. The Lancet Neurology,2010,9(5), Pages 469 480.
[43]卢全生,雷燕,陈可冀。AT1R基因多态性与原发性高血压中医证型及降压中药疗效的关系中国中西医结合杂志2005,25(8)：682-685.
[44]缪化春,沈业寿. 有关天麻多糖的降压作用. 高血压杂志,2006,14(7)：531-533.[45]苏金平,刘干中,彭继道.五种中草药对钙通道阻滞作用的初步研究.中药药理与临床,2006,22(6)：45-46.
[46]Vanninen E,Tuunainen M,Kansanen M,ET-1 al. Cardiac sympatho-vagal balance during sleep apnea episodes. Clin Physiol,1996,16 (3):209.
[47]张毓,钟晓明.中药颗粒剂成型工艺的研究进展.海峡药学2010,22(1)27：28.
[48]何龙,姚尧.中药颗粒剂的研究现状及应用前景分析.中医中药,2010,17(9)：82-83。